U.S. patent application number 14/116486 was filed with the patent office on 2014-05-15 for induction of immune tolerance by using methotrexate.
This patent application is currently assigned to GENZYME CORPORATION. The applicant listed for this patent is Richard Garman, Alexandra Joseph, Susan Richards, Melanie Ruzek. Invention is credited to Richard Garman, Alexandra Joseph, Susan Richards, Melanie Ruzek.
Application Number | 20140135337 14/116486 |
Document ID | / |
Family ID | 47177257 |
Filed Date | 2014-05-15 |
United States Patent
Application |
20140135337 |
Kind Code |
A1 |
Joseph; Alexandra ; et
al. |
May 15, 2014 |
INDUCTION OF IMMUNE TOLERANCE BY USING METHOTREXATE
Abstract
The invention provides methods for reducing undesired immune
responses, such as anti-drug antibody (ADA) responses and other T-
and/or B-cell-mediated immune responses, in patients by using
treatment with methotrexate.
Inventors: |
Joseph; Alexandra;
(Lexington, MA) ; Richards; Susan; (Sudbury,
MA) ; Ruzek; Melanie; (Acton, MA) ; Garman;
Richard; (Natick, MA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Joseph; Alexandra
Richards; Susan
Ruzek; Melanie
Garman; Richard |
Lexington
Sudbury
Acton
Natick |
MA
MA
MA
MA |
US
US
US
US |
|
|
Assignee: |
GENZYME CORPORATION
Cambridge
MA
|
Family ID: |
47177257 |
Appl. No.: |
14/116486 |
Filed: |
May 3, 2012 |
PCT Filed: |
May 3, 2012 |
PCT NO: |
PCT/US2012/036405 |
371 Date: |
January 6, 2014 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
61486697 |
May 16, 2011 |
|
|
|
Current U.S.
Class: |
514/249 |
Current CPC
Class: |
A61K 39/39558 20130101;
A61P 3/00 20180101; A61P 37/06 20180101; A61K 39/0008 20130101;
A61P 35/00 20180101; A61P 37/02 20180101; A61K 31/519 20130101;
A61P 7/06 20180101; A61P 25/00 20180101; A61P 37/00 20180101; A61K
45/06 20130101; A61P 43/00 20180101; A61K 31/519 20130101; A61K
2300/00 20130101; A61K 39/39558 20130101; A61K 2300/00
20130101 |
Class at
Publication: |
514/249 |
International
Class: |
A61K 31/519 20060101
A61K031/519 |
Claims
1-53. (canceled)
54. A method of increasing the efficacy of a therapeutic in a
subject in need of treatment with the therapeutic, comprising
administering to the subject an effective amount of methotrexate,
thereby increasing the efficacy of the therapeutic in the
subject.
55. The method of claim 54, wherein the effective amount of
methotrexate is administered in a single cycle.
56. The method of claim 55, wherein the single cycle of
methotrexate consists of 1 day of methotrexate administration or 2,
3, 4, 5, 6, 7, 8, 9, 10, or 11 consecutive days of methotrexate
administration.
57. The method of claim 55, wherein the single cycle of
methotrexate is administered between 48 hours prior to and 48 hours
after the onset of the therapeutic treatment.
58. The method of claim 54, wherein the method comprises: a.
inducing immune tolerance toward the therapeutic in the subject; b.
inhibiting antibody responses to the therapeutic in the subject; c.
alleviating an infusion reaction to the protein therapeutic in the
subject; d. reducing secondary autoimmunity in the subject; e.
increasing the percentage of T regulatory cells in the T cell
population in the subject; f. increasing the percentage of B
regulatory cells in the B cell population in the subject; or g.
inhibiting T cell responses in the subject.
59. The method of claim 54, wherein the subject is a human.
60. The method of claim 59, wherein the subject is a multiple
sclerosis patient, a patient who is in need of tissue
transplantation, a patient who is in need of organ transplantation,
a patient having aplastic anemia, or a patient having or is at risk
of having graft-versus-host disease.
61. The method of claim 54, wherein the therapeutic is a protein
therapeutic.
62. The method of claim 61, wherein the therapeutic is an antibody
therapeutic.
63. The method of claim 62, wherein the antibody therapeutic is a
monoclonal antibody therapeutic.
64. The method of claim 62, wherein the antibody therapeutic is a
lymphocyte-depleting agent.
65. The method of claim 64, wherein the antibody therapeutic is
alemtuzumab
66. The method of claim 64, wherein the monoclonal antibody
therapeutic is rituximab.
67. The method of claim 62, wherein the antibody therapeutic is a
polyclonal antibody therapeutic.
68. The method of claim 67, wherein the antibody therapeutic is
polyclonal rabbit anti-thymocyte globulin antibody.
69. The method of claim 61, wherein the therapeutic is an
enzyme.
70. The method of claim 69, wherein the enzyme is human
alpha-galactosidase A.
71. The method of claim 69, wherein the enzyme is human acid
alpha-glucosidase.
72. The method of claim 54, wherein the subject also receives
another agent for immune modulation.
73. The method of claim 72, wherein the agent for immune modulation
is an immunosuppressant.
Description
CROSS REFERENCE TO OTHER APPLICATIONS
[0001] This application claims priority from U.S. Provisional
Application No. 61/486,697, filed May 16, 2011, the disclosure of
which is incorporated herein by reference in its entirety.
FIELD OF THE INVENTION
[0002] This invention relates generally to immunology, and more
specifically to the use of methotrexate to reduce undesired immune
responses in patients.
BACKGROUND OF THE INVENTION
[0003] Currently, the U.S. Food and Drug Administration (FDA) has
approved more than 130 protein therapeutics for clinical use
(Leader et al., Nat Rev Drug Discov, 7(1):21-39 (2008)). These
therapeutics include peptides, recombinant human proteins, protein
vaccines, polyclonal antibody preparations derived from a variety
of animal species, and monoclonal antibodies. Depending upon their
sequence and conformational homology to endogenous self-antigens,
glycosylation status, dose level, route of administration,
localization, and manufacturing process-related characteristics,
the therapeutic proteins may elicit antibody responses in the
patient (Schellekens, Nat Rev Drug Discov, 1(6):457-62 (2002);
Zinkernagel, Semin Immunol, 12(3):163-71 (2000), discussion
257-344; Thorland et al., Haemophilia, 5(2):101-5 (1999); Goodeve,
Blood Coagul Fibrinolysis, 14 Suppl 1:S17-21 (2003)). These
responses, referred to as anti-drug antibody (ADA) responses, can
impact patient safety and drug efficacy sometimes.
[0004] In the case of the lysosomal storage disorder, Pompe
disease, ADA can develop in the enzyme-replacement therapy (ERT)
against recombinant human acid alpha-glucosidase. In patients who
do not express measurable amounts of the endogenous enzyme,
sustained levels of high antibody titer correlate with patient
decline (CRIM-Pompe patients) (Kishnani et al., Mol Genet Metab.,
99(1):26-33 (2010); Hunley et al., Pediatrics, 114(4):e532-5
(2004); Amalfitano et al., Genet Med, 3(2): 132-8 (2001)). Similar
compromise in drug safety and efficacy has been observed in
hemophilia patients who develop ADA to factor IX (Thorland et al.,
Haemophilia, 5(2):101-5 (1999); Ewenstein et al., Blood,
89(3):1115-6 (1997)). In rare instances, ADA can also induce
autoimmune disease as in the case of recombinant human
erythropoietin (Schellekens, Clin Ther, 24(11):1720-40 (2002),
discussion 1719; Locatelli et al., Perit Dial Int, 27 Suppl
2:S303-7 (2007)).
[0005] ADA responses can also occur with antibody therapeutics
regardless of whether the therapeutics are non-human derived,
humanized or even fully human. The immunogenicity of both
monoclonal and polyclonal antibody therapeutics can influence
patient safety and drug efficacy. Antibodies that develop against
therapeutic monoclonal antibodies such as infliximab, adalimumab,
rituximab and natalizumab have been associated with decreased serum
levels and efficacy of the therapeutic antibodies (Bendtzen et al.,
Arthritis Rheum, 54(12):3782-9 (2006); Schmidt et al., Clin
Immunol, 132(3):334-41 (2009); Bartelds et al., Ann Rheum Dis,
66(7):921-6 (2007); Baert et al., N Engl J Med, 348(7):601-8
(2003); Tahir et al., Rheumatology (Oxford), 44(4):561-2 (2005);
Maini et al., Arthritis Rheum, 41(9):1552-63 (1998)). Allergic
reactions have been associated with anti-infliximab antibodies
(Baert et al., N Engl J Med, 348(7):601-8 (2003)). Infusion-related
hypersensitivity reactions have been observed in a small percentage
of relapsing-remitting multiple sclerosis patients treated with
natalizumab (Phillips et al., Neurology, 67(9):1717-8 (2006)).
[0006] Alemtuzumab is another antibody therapeutic that can
generate ADA in relapsing-remitting multiple sclerosis patients
(Coles et al., N Engl J Med, 2008. 359(17):1786-801 (2008)).
Alemtuzumab is a lymphocyte-depleting monoclonal antibody that
interacts with CD52, a cell surface antigen expressed on immune
cells. Alemtuzumab is in late-stage clinical trials for treating
relapsing-remitting multiple sclerosis and has also been evaluated
in rheumatoid arthritis. A group of researchers have shown that
anti-alemtuzumab antibodies developed in 63% of rheumatoid
arthritis patients treated in a single dose escalation study
(Weinblatt et al., Arthritis Rheum, 1995. 38(11):1589-94 (1995)).
In that study, the efficacy of alemtuzumab appeared to be altered
by the presence of ADA (Id.).
[0007] The polyclonal antibody therapeutic Thymoglobulin.RTM. is
also associated with deleterious ADA in a small subset of patients.
Serum sickness, acute renal failure and cardiovascular reactions
have been observed in Thymoglobulin.RTM.-treated transplant
recipients (Boothpur et al., Am J Kidney Dis., 55(1):141-3 (2009);
Lundquist et al., Liver Transpl, 13(5):647-50 (2007); Busani et
al., Minerva Anestesiol, 72(4):243-8 (2006); Tanriover et al.,
Transplantation, 80(2):279-81 (2005); Buehler et al., Clin
Transplant, 17(6):539-45 (2003)).
[0008] Researches have tried to find ways to minimize the
deleterious effects of ADA. Tools that have been tested for their
ability to induce immunotolerance and reduce ADA in protein
therapies include, for example, non-depleting anti-CD4 antibodies
(Cobbold et al., Semin Immunol, 2(6):377-87 (1990); Winsor-Hines et
al., J Immunol, 173(7): 4715-23 (2004)), non-cell-binding minimal
mutants of alemtuzumab (Gilliland et al., J Immunol, 162(6):3663-71
(1999); Somerfield et al., J Immunol., 185(1):763-8 (2010)),
immunosuppressive therapies (Bennett et al., Blood, 106(10):3343-7
(2005); Dickson et al., J Clin Invest, 118(8):2868-76 (2008)),
phosphatidylinositol-containing lipidic particles binding to Factor
VIII (Peng et al., AAPS. J., 12(3):473-81 (2010)), and
liver-specific administration of recombinant acid alpha-glucosidase
via adeno-associated virus infection (Sun et al., Am J Human Genet,
81(5):1042-9 (2007); Sun et al., Mol Ther 18(2):353-60 (2009);
Ziegler et al., Hum Gene Ther, 19(6):609-21 (2008)). There remains
a need, however, to develop improved methods for reducing undesired
antibody responses in protein therapies and other settings.
SUMMARY OF THE INVENTION
[0009] The invention provides a method of inducing immune tolerance
in a subject in need of treatment with a therapeutic. In this
method, one administers to the subject an effective amount of
methotrexate in a single cycle, thereby inducing immune tolerance
toward the therapeutic in the subject.
[0010] The invention also provides a method of inhibiting antibody
responses to a therapeutic in a subject in need of treatment with
the therapeutic. In this method, one administers to the subject an
effective amount of methotrexate in a single cycle, thereby
inhibiting antibody responses to the therapeutic in the
subject.
[0011] The invention also provides a method of alleviating an
infusion reaction to a therapeutic in a subject in need of
treatment with the therapeutic. In this method, one administers to
the subject an effective amount of methotrexate, thereby
alleviating an infusion reaction to the protein therapeutic in the
subject.
[0012] The invention also provides a method of reducing secondary
autoimmunity in an autoimmune subject in need of treatment with a
therapeutic. In this method, one administers to the subject an
effective amount of methotrexate, thereby reducing secondary
autoimmunity in the subject.
[0013] The invention also provides a method of increasing the
efficacy of a therapeutic in a subject in need of treatment with
the therapeutic. In this method, one administers to the subject an
effective amount of methotrexate, thereby increasing the efficacy
of the protein therapeutic in the subject.
[0014] The invention also provides a method of increasing the
percentage of T regulatory cells in the T cell population in a
subject treated with a lymphocyte-depleting therapy, e.g., an
alemtuzumab therapy or a Thymoglobulin.RTM. therapy. In this
method, one administers to the subject an effective amount of
methotrexate, thereby increasing said percentage in said
subject.
[0015] The invention also provides a method of increasing the
percentage of B regulatory cells in the B cell population in a
subject in need of treatment with a protein therapeutic such as an
antibody therapeutic. In this method, one administers to the
subject an effective amount of methotrexate, thereby increasing
said percentage in said subject. In some embodiments, the effective
amount of methotrexate is administered in a single cycle. In
related embodiments, the invention provides a method of increasing
TGF-beta-, IL-10-, and/or FoxP3-expressing B cells in a subject in
need of treatment with a protein therapeutic, comprising
administering an effective amount of methotrexate in a single
cycle.
[0016] The invention also provides a method of prolonging the
pharmacokinetics of a therapeutic agent in a subject. In this
method, one administers methotrexate to the subject, before or
during or after administration of the therapeutic agent, in an
amount effective to prolong the pharmacokinetics of the therapeutic
agent.
[0017] The invention further provides a method of depleting
lymphocytes in a human patient in need thereof. In this method, one
treats the patient with a lymphocyte-depleting agent and
administers methotrexate to the patient, before or during or after
the treatment with the lymphocyte-depleting agent, in an amount
effective to induce immune tolerance in the patient toward the
lymphocyte-depleting agent or to reduce secondary autoimmunity. In
some embodiments, the effective amount of methotrexate is
administered in a single cycle. In some embodiments, the
lymphocyte-depleting agent may be a monoclonal antibody therapeutic
(e.g., alemtuzumab or rituximab). In certain of these embodiments,
the patient may be a multiple sclerosis patient (e.g., a
remitting-relapsing multiple sclerosis patient). In some
embodiments, the lymphocyte-depleting agent may be a polyclonal
antibody therapeutic (e.g., anti-thymocyte globulin polyclonal
antibody).
[0018] The invention also provides a method of inducing immune
tolerance in a subject in need of tissue transplantation. In this
method, one administers to the subject an effective amount of
methotrexate, thereby inducing immune tolerance toward the
transplanted tissue in the subject. In some embodiments, the
effective amount of methotrexate is administered in a single cycle.
In some embodiments, the transplanted tissue is renal tissue or
cardiac tissue. In some embodiments, the subject also receives an
agent for immune-modulation (e.g., an immunosuppressant), such as
polyclonal anti-thymocyte globulin antibody).
[0019] The invention also provides a method of inhibiting T cell
responses in a subject in need of a therapeutic or tissue
transplantation. In this method, one administers to the subject an
effective amount of methotrexate prior to, concurrently with, or
after, treating the subject with the therapeutic or tissue
transplantation, thereby inhibiting T cell responses in the
subject.
[0020] In some embodiments of the methods of the invention, the
therapeutic is a protein therapeutic.
[0021] In some embodiments of the methods of the invention, the
therapeutic is an antibody therapeutic. For example, the antibody
therapeutic may be a monoclonal antibody therapeutic and/or a
lymphocyte-depleting agent (e.g., alemtuzumab), or a polyclonal
antibody therapeutic (e.g., polyclonal rabbit anti-thymocyte
globulin antibody). In further embodiments wherein the antibody
therapeutic is alemtuzumab, the subject may be a multiple sclerosis
patient. In further embodiments wherein the antibody therapeutic is
polyclonal rabbit anti-thymocyte globulin antibody, the subject may
be a human patient who is in need of organ transplantation, has
aplastic anemia, and/or has or is at risk of having
graft-versus-host disease. In other embodiments of the methods of
the invention, the therapeutic is an enzyme. For example, the
enzyme may be human alpha-galactosidase A or human acid
alpha-glucosidase.
[0022] In some embodiments of the methods of the invention, the
subject is a human.
[0023] In some embodiments of the methods of the invention, the
effective amount of methotrexate may be 0.1 mg/kg to 5 mg/kg. In
some embodiments, the single cycle of methotrexate may consist of 1
day of methotrexate administration, or 2, 3, 4, 5, 6, 7, 8, 9, 10,
or 11 consecutive days of methotrexate administration. In some
embodiments, the single cycle of methotrexate may be administered
between 48 hours prior to and 48 hours after the onset of the
therapeutic treatment.
BRIEF DESCRIPTION OF THE FIGURES
[0024] In each of the Figures described below, asterisks or stars
indicate measurements with statistically significant differences
(*, p<0.05; **, p.ltoreq.0.001; ***, p.ltoreq.0.0001).
[0025] FIGS. 1A-B show anti-rabbit IgG responses to a single and
multiple courses of mATG, a rabbit anti-murine thymocyte globulin
polyclonal antibody. Average anti-rabbit IgG titers were measured,
and mice treated with rabbit IgG (rbIgG) only were used as a
control. FIG. 1A shows responses to a single course of mATG over an
8 week period. FIG. 1B shows responses to multiple courses of mATG
over a 20 week period. Arrows indicate time points at which mATG or
rbIgG were administered.
[0026] FIG. 2 shows average alemtuzumab-specific IgG titers
following five monthly treatments with alemtuzumab. Arrows indicate
time points at which alemtuzumab was administered.
[0027] FIG. 3 shows suppression of anti-mATG IgG responses by
methotrexate (MTX) following a single course of mATG. Mice were
treated with mATG only, rbIgG only, or mATG and methotrexate.
[0028] FIGS. 4A-C show the effects of methotrexate on anti-rabbit
IgG responses throughout a course of five monthly treatments with
mATG. Arrows indicate time points at which mATG or methotrexate
were administered. FIG. 4A shows that three cycles of methotrexate
significantly reduce average anti-rabbit IgG titers. FIG. 4B shows
that a single course of methotrexate significantly reduces average
anti-rabbit IgG titers. FIG. 4C compares the average anti-rabbit
IgG titers of mice treated with mATG alone, mATG and a single cycle
of methotrexate, or mATG and three cycles of methotrexate. A single
cycle of methotrexate reduces anti-rabbit IgG titers more
significantly than three cycles of methotrexate.
[0029] FIG. 5 shows that average anti-rabbit IgG titers are reduced
after mATG re-challenge in methotrexate-treated mice (single and
multiple methotrexate cycles), as compared to mice treated with
mATG but not methotrexate. Arrows indicate time points at which
mATG or methotrexate were administered.
[0030] FIG. 6 shows that the average anti-rabbit IgG titer in mice
treated with mATG and a single cycle of methotrexate is 100 fold
less than that in mice treated with mATG alone. Arrows indicate
time points at which mATG or methotrexate were administered.
[0031] FIGS. 7A-C show that methotrexate can reduce average
anti-alemtuzumab IgG titers in huCD52 Tg mice. FIG. 7A:
Anti-alemtuzumab titers are lower in mice treated with a single
cycle of 1 mg/kg or 5 mg/kg of methotrexate than in mice treated
with 0.5 mg/kg or no methotrexate. Mice were treated with
alemtuzumab alone, or alemtuzumab and a single cycle of
methotrexate at 0.5 mg/kg, 1 mg/kg, or 5 mg/kg. FIG. 7B: Study
design to test anti-alemtuzumab titers. Titer data was determined
at 24 hours following the fifth dose of alemtuzumab, as indicated
by the star. FIG. 7C: Methotrexate reduced anti-alemtuzumab
antibody titers in mice receiving alemtuzumab and methotrexate,
compared to mice receiving only alemtuzumab, 24 hours after the
fifth dose of alemtuzumab.
[0032] FIGS. 8A-D show the absolute cell number/.mu.l of whole
blood of circulating T cells in mice treated with five daily doses
of 0.5 mg/kg alemtuzumab or phosphate-buffered saline (PBS). FIG.
8A shows that total T cells (CD3.sup.+) were reduced two, three,
and four weeks post-treatment. FIG. 8B shows that total B cells
(CD19.sup.+) were reduced three weeks post-treatment. FIG. 8C shows
that T helper cells (CD4.sup.+) were reduced at two, three, and
four weeks post-treatment, and FIG. 8D shows that cytotoxic T cells
(CD8.sup.+) were reduced at two, three, and four weeks
post-treatment.
[0033] FIGS. 9A-B show alemtuzumab-specific IgG responses. FIG. 9A
shows responses following three cycles of treatment with
alemtuzumab at 0.5 mg/kg, and one cycle of treatment with
methotrexate at 0.5 mg/kg, 1 mg/kg, or 2 mg/kg. The first cycle of
alemtuzumab treatment consisted of five consecutive days of dosing,
and the second and third cycles each consisted of three consecutive
days of dosing. FIG. 9B shows anti-alemtuzumab IgG titers of each
animal per group at week 14.
[0034] FIG. 10 shows that a single cycle of 5 mg/kg of methotrexate
restores circulating mATG levels in mice treated with five monthly
doses of mATG.
[0035] FIG. 11 shows that mice treated with five monthly treatments
of mATG and a single cycle of methotrexate have enhanced
mATG-mediated CD4.sup.+ and CD8.sup.+ T cell depletion in blood
after the fifth dose of mATG. These data are pooled from two
experiments.
[0036] FIGS. 12A-B show that mice treated with a single cycle of
methotrexate exhibit increased percentages of T regulatory
(CD25.sup.+Foxp3.sup.+) cells following a fifth monthly mATG
treatment. Mice were treated with five monthly treatments of mATG
alone, or five monthly treatment of mATG and a single cycle of
methotrexate, or five monthly treatments of mATG and three cycles
of methotrexate. FIG. 12A shows T regulatory cell levels in the
spleen. FIG. 12B shows T regulatory cell levels in the blood.
[0037] FIG. 13A shows that an anti-rabbit IgG titer greater than
10,000 can interfere with pharmacokinetics of mATG. FIG. 13B shows
that an anti-rabbit titer greater than 100,000 can interfere with
CD4 and CD8 cell depletion. % of pretreatment control refers to the
percent of CD4 and CD8 titers relative to their respective levels
prior to mATG treatment.
[0038] FIG. 14 shows that mice treated with 5 mg/kg of methotrexate
exhibit enhanced alemtuzumab depletion of circulating CD3.sup.+ T
cells and CD19.sup.+ B cells after a fifth monthly dose of
alemtuzumab. Mice were treated with alemtuzumab alone, or
alemtuzumab and a single cycle of methotrexate for the first three
days of the study. Asterisks indicate measurements with
statistically significant differences (*, p<0.05; ***,
p.ltoreq.0.0001).
[0039] FIG. 15A shows that a single cycle of methotrexate can
reduce recombinant human acid alpha-glucosidase (rhGAA)-specific
IgG titers throughout treatment, and even four weeks after the last
rhGAA treatment, in a 16-week study. Arrows indicate time points at
which rhGAA and methotrexate were administered. Mice were treated
with rhGAA alone, or rhGAA and a single cycle of methotrexate, or
rhGAA and three cycles of methotrexate. FIG. 15B shows that, in a
six-week study, a single cycle of methotrexate reduces
rhGAA-specific IgG titers. FIG. 15C shows that a single cycle of
methotrexate reduces rhGAA-specific IgG titers in an 18 week
study.
[0040] FIG. 16A shows that methotrexate decreases anti-rabbit IgG
titers in a murine allogeneic heart transplant model when
administered with mATG, as compared to mATG alone. FIG. 16B shows
that methotrexate increases circulating levels of mATG in a murine
allogeneic heart transplant model. Mice were treated with saline,
mATG alone, or mATG and a single cycle of methotrexate. mATG was
administered at 20 mg/kg at days 0 and 4 of the study, while 2
mg/kg of methotrexate was administered on days 0-6 of the
study.
[0041] FIG. 17 shows a Kaplan-Meier plot indicating that a combined
treatment of mATG and methotrexate prolongs the survival of
allogeneic hearts transplanted into recipient mice. Mice were left
untreated, or were treated with 20 mg/kg of mATG alone at days 0
and 4 of the study, or with 2 mg/kg of methotrexate alone on days
0-6 of the study, or with both mATG and 2 mg/kg of methotrexate on
days 0-6, or with both mATG and 0.5 mg/kg of methotrexate on days
0-6 or days 0-11.
[0042] FIG. 18 shows that mice with an allogeneic heart
transplanted treated with either methotrexate alone or methotrexate
in combination with mATG experience a reduction in anti-allograft
antibody responses. FIG. 18A shows recipient IgG binding to
allogeneic fibroblasts on day 21. FIG. 18B shows alloantibody
levels on day 21 in mice given syngeneic transplants (Syn Tx) or an
allogeneic transplant (Allo Tx) with the indicated treatments.
Shown is the binding of individual recipient mouse serum IgG to
allogeneic fibroblasts and is expressed as a ratio of the mean
fluorescence intensity (MFI) to unstained fibroblasts. FIG. 18C
shows alloantibody levels on day 21 in mice given no treatment,
mATG, methotrexate, or mATG and methotrexate. Alloantibody levels
were significantly lower in mice treated with methotrexate or mATG
and methotrexate (p=0.0008 and p<0.0001, respectively).
[0043] FIG. 19 shows that B10 regulatory B cells are significantly
increased following methotrexate treatment. Mice were treated with
rhGAA alone or rhGAA and a single three-day cycle of methotrexate
or saline. Cell numbers were counted on day 7 and day 8 of the
study.
[0044] FIG. 20 shows that activated B cell subpopulations are
significantly increased on day 6 following treatment with rhGAA and
a single three-day cycle of methotrexate, as compared to treatment
with rhGAA alone. Absolute cell numbers of CD86+ transitional 2 B
cells, CD86+ transitional 3 B cells, CD86+ follicular B cells, and
CD86+ marginal zone B cells were counted on day 6 of the study.
Asterisks indicate measurements with statistically significant
differences (*, p<0.05; **, p.ltoreq.0.001).
[0045] FIG. 21 shows that for activated splenic B cell
subpopulations, such as activated marginal zone B cells, activated
follicular B cells, and activated transitional 3 B cells, cell
numbers remain enhanced even following treatment with rhGAA and
methotrexate, as compared to treatment with rhGAA alone. Arrows
represent the treatment with rhGAA and methotrexate. rhGAA was
administered on day 1 and day 8. Methotrexate was administered on
days 1, 2, and 3, and days 8, 9, and 10. Significant differences
are represented by stars (*, p<0.05). Data not shown for days 8
and 9 (indicated by vertical dotted lines).
[0046] FIG. 22 shows that activated splenic T cell populations,
such as activated T helper cells, activated T cytotoxic cells, and
activated T regulatory cells, remain largely unchanged following
treatment with rhGAA and methotrexate, as compared to treatment
with rhGAA alone. Arrows represent the treatment with rhGAA and
methotrexate. rhGAA was administered on day 1 and day 8.
Methotrexate was administered on days 1, 2, and 3, and days 8, 9,
and 10. Significant differences are represented by stars (*,
p<0.05). Data not shown for days 8 and 9 (indicated by vertical
dotted lines).
[0047] FIG. 23 shows a six month-long study design for examining
methotrexate treatment in combination with mATG. Solid arrows
represent 5 mg/kg mATG injections, dashed arrows represent 5 mg/kg
methotrexate injections, and dotted arrows represent terminal
sacrifices.
[0048] FIGS. 24A-B show that a single cycle of methotrexate in
connection with mATG enriches splenic B cells, as compared to mATG
alone or three cycles of methotrexate. FIG. 24A: activated
follicular B cells; FIG. 24B: activated transitional 3 B cells.
[0049] FIGS. 25A-B show the effects of methotrexate on
alemtuzumab's pharmacodynamics in the blood. Mice were treated with
0.5 mg/kg of alemtuzumab for five months, either with or without
three daily doses of 5 mg/kg/day of methotrexate in connection with
the first administration of alemtuzumab. FIG. 25A: Methotrexate
enhances depletion of total T cells (CD3.sup.+), T helper cells
(CD4.sup.+), and T regulatory cells
(CD4.sup.+CD25.sup.+Foxp3.sup.+) by alemtuzumab (AZM). Black bars
represent measurements in mice treated with alemtuzumab alone,
while white bars represent measurements in mice treated with
alemtuzumab and methotrexate. FIG. 25B: Methotrexate enhances
depletion of B cells by alemtuzumab. Stars indicate measurements
with statistically significant differences (*, p<0.05).
[0050] FIG. 26 shows the effects of methotrexate on alemtuzumab's
pharmacodynamics in the spleen. Mice were treated with 0.5 mg/kg of
alemtuzumab for five months, either with or without three daily
doses of 5 mg/kg/day of methotrexate in connection with the first
administration of alemtuzumab. T cells are depleted following the
fifth treatment with alemtuzumab. CD8 CEN: CD8.sup.+ central memory
T cells; CD8 EFF MEM: CD8.sup.+ effector memory T cells; CD4 CEN
MEM: CD4.sup.+ central memory T cells; CD4 EFF MEM: CD4.sup.+
effector memory T cells. Stars indicate measurements with
statistically significant differences (*, p<0.05).
[0051] FIGS. 27A-B show the effects of methotrexate on B cell
numbers in the spleen. Mice were treated with 0.5 mg/kg of
alemtuzumab for five months, either with or without three daily
doses of 5 mg/kg/day of methotrexate in connection with the first
administration of alemtuzumab. Stars indicate measurements with
statistically significant differences (*, p<0.05).
[0052] FIGS. 28A-B show depletion of splenic lymphocytes three days
after a single dose of alemtuzumab. FIG. 28A: T cells and B cells
are significantly depleted. Small checks represent PBS-treated
control mice, and large checks represent alemtuzumab-treated mice.
FIG. 28B: B cells (CD 19.sup.+) are 92% depleted at 24 hours after
treatment, and remain 36% depleted three days after treatment. The
three graphs represent different group of animals, each of which
was bled at different time points. Stars indicate measurements with
statistically significant differences (*, p<0.05; **,
p.ltoreq.0.001; ***, p.ltoreq.0.0001).
[0053] FIGS. 29A-B show the effects of methotrexate on cytokine
levels. FIG. 29A shows a study design for a six month study to
assess cytokine levels in the spleen and lymph nodes. The star
indicates that data were collected 24 hours after the fifth
treatment with alemtuzumab. Arrows indicate time points at which
alemtuzumab or methotrexate were administered, or terminal
sacrifices were performed, as indicated. FIG. 29B shows levels of B
cell activating factor belonging to the TNF family (BAFF) in mice
treated with alemtuzumab alone or with alemtuzumab and
methotrexate.
[0054] FIGS. 30A-B show the levels of cytokines after treatment
with alemtuzumab and methotrexate. FIG. 30A shows a study design
for a four month study. The star indicates that data were collected
one week after the second cycle of methotrexate. Arrows indicate
time points at which alemtuzumab or methotrexate were administered,
or terminal sacrifices were performed, as indicated. FIG. 30B shows
the levels of various cytokines in mice treated with alemtuzumab
(AZM) alone or with 0.5 mg/kg, 1.0 mg/kg, or 2.0 mg/kg of
methotrexate.
[0055] FIG. 31 shows the effects of methotrexate on anti-rhGAA
titers in IL10-/- (knockout) and C57BL/6 mice. 20 mg/kg of rhGAA
was administered weekly for nine weeks in IL10-/- knockout mice and
C57BL/6 wild-type mice, with or without 5 mg/kg/day of methotrexate
at 0, 24, and 48 hours after the first three weekly treatments of
rhGAA.
[0056] FIG. 32 shows that some, but not all, splenic B cell
populations are depleted at one and/or two weeks following
treatment with alemtuzumab. Small hatched bars represent phosphate
buffered saline (PBS) treated huCD52 transgenic control mice; large
hatched bars depict huCD52 transgenic mice treated with 0.5 mg/kg
of alemtuzumab for five consecutive days. Asterisks indicate
measurements with statistically significant differences (*,
p<0.05; **, p.ltoreq.0.001; ***, p.ltoreq.0.0001).
[0057] FIG. 33 shows a study design for examining the effects of
methotrexate on B cell populations in the context of treatment with
alemtuzumab. Thyroid and lymph nodes (LN) were used for
pathological evaluation. Arrows indicate time points at which
alemtuzumab and methotrexate were administered, or terminal
sacrifices as indicated.
[0058] FIG. 34 shows the effects of three daily doses of 5
mg/kg/day methotrexate alone, 0.5 mg/kg alemtuzumab alone, and 0.5
mg/kg alemtuzumab and 5 mg/kg/day methotrexate in combination on
the depletion of B cell populations. Asterisks indicate
measurements with statistically significant differences (*,
p<0.05; **, p.ltoreq.0.001; ***, p.ltoreq.0.0001); ns, not
significant).
[0059] FIG. 35 shows the effects of methotrexate on B cell
depletion after five cycles of treatment with 0.5 mg/kg alemtuzumab
alone or three daily doses of 5 mg/kg/day methotrexate alone or 0.5
mg/kg alemtuzumab and 5 mg/kg/day methotrexate in combination.
Asterisks indicate measurements with statistically significant
differences (*, p<0.05).
[0060] FIG. 36 shows that levels of the cytokines MCP-1, IL-13,
IL-6, and IL-12 are decreased in mice treated with a single cycle
of three days of 5 mg/kg of methotrexate administered on the first
day of alemtuzumab treatment. Data were collected 24 hours after a
fifth dose of alemtuzumab, four months after treatment with
methotrexate.
[0061] FIGS. 37A-B show rhGAA titers at weeks 2, 6, and 12 in nu/nu
nude mice. FIG. 37A shows rhGAA titers at weeks 2 and 6. From left
to right, week 2 measurements in control mice treated with saline,
mice treated with rhGAA, and mice treated with rhGAA and
methotrexate, followed by week 6 measurements in control mice
treated with saline, mice treated with rhGAA, and mice treated with
rhGAA and methotrexate. FIG. 37B shows week 12 measurements in,
from left to right, nu/nu mice treated with rhGAA alone (Myo),
nu/nu mice treated with methotrexate and rhGAA, BL6 mice treated
with rhGAA alone, and BL6 treated with methotrexate and rhGAA.
[0062] FIGS. 38A-B show that the numbers and percentages of IL-10
expressing B10 B cells is increased in mice tolerized to rhGAA with
methotrexate. B 10 B cells isolated from animals treated with rhGAA
or rhGAA and methotrexate were assessed for IL-10 protein
expression by flow cytometry.
[0063] FIGS. 39A-B show that IL-10 is expressed in both activated
(CD86+) and non-activated (CD86-) B10 B cells. FIG. 39A depicts a
FACS plot of B10 B cells stained with CD86, while FIG. 39B depicts
the numbers of CD86.sup.+IL10.sup.+ B10 B cells and CD86.sup.-
IL10.sup.+ B10 B cells in response to treatment with rhGAA or rhGAA
and methotrexate.
[0064] FIGS. 40A-B show that methotrexate treatment with rhGAA
induces B10 B cells to increase their expression of TGF-beta. The
second and third panels of FIG. 40A are FACS plots showing B10 B
cells stained with TGF-beta and CD86 from animals treated with
rhGAA or rhGAA and methotrexate. The first panel of FIG. 40A
depicts the number of TGF-beta.sup.+ B 10 B cells in animals
treated with rhGAA or rhGAA and methotrexate. FIG. 40B depicts
CD86.sup.+TGF-beta.sup.+ B10 B cell and CD86.sup.-TGF-beta.sup.+
B10 B cell counts.
[0065] FIG. 41A depicts that B10 B cells appear to express FoxP3 in
animals treated with rhGAA (FIG. 41A). FIG. 41B depicts that the
numbers of FoxP3+ B cells increase with treatment with both
methotrexate and rhGAA. FIG. 41C depicts that both activated
(CD86+) and non-activated (CD86-) B10 B cells express FoxP3.
[0066] FIGS. 42A-C show that follicular, transitional 2, and
transitional 3 B cells (top to bottom) express IL-10 and that the
cell numbers of the IL-10-expressing B cell subsets increase with
methotrexate as compared to mice treated with rhGAA alone.
[0067] FIGS. 43A-C show that follicular, transitional 2, and
transitional 3 B cells (top to bottom) express TGF-beta and that
the cell numbers of the TGF-beta-expressing B cell subsets increase
with methotrexate as compared to mice treated with rhGAA alone.
[0068] FIGS. 44A-C show that follicular, transitional 2, and
transitional 3 B cells (top to bottom) express FoxP3 and that the
cell numbers of the FoxP3-expressing B cell subsets increase with
methotrexate as compared to mice treated with rhGAA alone.
[0069] FIG. 45 shows anti-rhGAA titers at week 6 in animals treated
with rhGAA or rhGAA and methotrexate, in the presence or absence of
5 mg/kg of anti-TGF-beta antibody (1D11, Genzyme) or the isotype
control (13C4). Antibody titers were assessed bi-weekly in the four
different groups of animals.
[0070] FIGS. 46A-C show that 1D11 treatment interfered with
methotrexate-induced expansion of B10 B cells expressing TGF-beta,
IL-10, or FoxP3. Spleens were isolated from animals treated with
rhGAA or rhGAA and methotrexate that also were co-administered 1D11
or 13C4 seven days following a single rhGAA treatment or a single
rhGAA and methotrexate treatment. Cells in each group were then
pooled and cultured for two days and then counted using flow
cytometry.
[0071] FIGS. 47A-C show that 1D11 treatment interfered with
methotrexate-induced expansion of follicular B cells expressing
TGF-beta or IL-10, although FoxP3+ Follicular B cells did not
appear to experience 1D11 effects. Spleens were isolated from
animals treated with rhGAA or rhGAA and methotrexate that also were
co-administered 1D11 or 13C4 seven days following a single rhGAA
treatment or a single rhGAA and methotrexate treatment. Cells in
each group were then pooled and cultured for two days and then
counted using flow cytometry.
[0072] FIGS. 48A-C show that, in transitional 2 B cells, while 1D11
treatment interfered with methotrexate-induced expansion of
TGF-beta-expressing transitional 2 B cells, no effects were seen on
IL-10+ transitional 2 B cells. Spleens were isolated from animals
treated with rhGAA or rhGAA and methotrexate that also were
co-administered 1D11 or 13C4 seven days following a single rhGAA
treatment or a single rhGAA and methotrexate treatment. Cells in
each group were then pooled and cultured for two days and then
counted using flow cytometry.
[0073] FIGS. 49A-C show that in transitional 3 B cells there is
detectable TGF-beta, IL-10 and FoxP3, but no apparent effect of
1D11 treatment on the cells. Spleens were isolated from animals
treated with rhGAA or rhGAA and methotrexate that also were
co-administered 1D11 or 13C4 seven days following a single rhGAA
treatment or a single rhGAA and methotrexate treatment, and cells
were counted using flow cytometry.
[0074] FIGS. 50A-C show that 1D11 treatment does not affect basal
levels of IL-10, TGF-beta, and FoxP3 in follicular B cells,
transitional 2 B cells, and transitional 3 B cells (top to
bottom).
[0075] FIG. 51A is a schematic showing the transfer of total
splenic B cells from a mouse tolerized to rhGAA (Myozyme.RTM. or
"MYO") into an rhGAA-naive recipient mouse. After transfer, the
recipients (along with non-transferred control animals treated with
either rhGAA or rhGAA and methotrexate) were treated weekly with 20
mg/kg of rhGAA.
[0076] FIG. 51B shows titer analysis demonstrating that total
splenic B cells isolated from animals treated with rhGAA and single
cycle of methotrexate can transfer immune tolerance to rhGAA in
naive hosts.
[0077] FIG. 52 depicts cell counts from the blood or spleen of
normal mice treated with rabbit IgG (rbIgG), mATG alone, rbIgG and
methotrexate, or mATG and methotrexate. Methotrexate does not
deplete CD4+, CD8+, T regulatory (CD4+CD25+FoxP3+) T cells, or
total CD 19+ B cells in normal animals.
[0078] FIG. 53 depicts cell counts from the blood or spleen of
transplant mice treated with rbIgG, mATG alone, rbIgG and
methotrexate, or mATG and methotrexate 14 days after
transplantation. Methotrexate does not deplete CD4+, CD8+, T
regulatory (CD4+CD25+FoxP3+) T cells, and total CD19+ B cells in
transplant animals.
[0079] FIG. 54 shows that methotrexate treatment induces
statistically significant increases in IL-10 in multiple cell
subsets as viewed by a shift in mean fluorescence intensity (MFI)
of these proteins in animals treated with rhGAA or rhGAA and
methotrexate.
[0080] FIG. 55 shows that methotrexate treatment induces
statistically significant increases in TGF-beta in multiple cell
subsets as viewed by a shift in mean fluorescence intensity (MFI)
of these proteins in animals treated with rhGAA or rhGAA and
methotrexate.
[0081] FIG. 56 shows that methotrexate treatment induces
statistically significant increases in FoxP3 in multiple cell
subsets as viewed by a shift in mean fluorescence intensity (MFI)
of these proteins in animals treated with rhGAA or rhGAA and
methotrexate.
DETAILED DESCRIPTION OF THE INVENTION
[0082] The present invention is based on our surprising discovery
that a single cycle or short course of methotrexate administration
reduces undesired immune responses (such as ADA responses, and
other undesired T- and/or B-cell mediated immune responses) in
patients receiving protein therapeutics such as replacement enzymes
or therapeutic antibodies, and anti-graft antibody responses in
tissue transplantation. This discovery leads to new methods for
increasing both safety and efficacy of protein therapies and organ
transplantation.
[0083] More specifically, our studies have shown that a single
cycle of methotrexate reduces ADA against antibody therapeutics. As
detailed below, one set of studies was done with a murine version
of a polyclonal antibody therapeutic, Thymoglobulin.RTM..
Thymoglobulin.RTM. is a rabbit anti-human thymocyte globulin
polyclonal antibody used for immunosuppression in the setting of
solid organ transplantation, aplastic anemia and in prevention of
graft-versus-host disease. A rabbit anti-murine thymocyte globulin
polyclonal antibody (mATG) has been developed. It maintains similar
characteristics to Thymoglobulin.RTM. (Ruzek, et al.,
Transplantation, 88(2):170-9 (2009)). We have demonstrated that a
single course of methotrexate can reduce anti-mATG IgG titers by
>95%. In fact, we have surprisingly found that a single cycle of
methotrexate works better in reducing ADA than three cycles of
methotrexate. In addition, this reduction in ADA maintains the
levels of circulating mATG and enhances mATG-mediated cell
depletion and T regulatory cell percentages upon repeat mATG
dosing. Another set of our studies was done with a monoclonal
antibody therapeutic, alemtuzumab. We have found that a single
course of methotrexate can similarly control anti-alemtuzumab
responses and enhance alemtuzumab-mediated lymphocyte
depletion.
[0084] We have discovered that this single cycle regimen of
methotrexate also reduces ADA where the protein therapeutic is an
enzyme. In two of our studies, we demonstrated that a single cycle
of methotrexate could effectively control
anti-Myozyme.RTM.(recombinant human alglucosidase alpha or "rhGAA")
responses where originally multiple cycles were thought to be
required to reduce ADA.
[0085] We have discovered that methotrexate is also useful in organ
transplantation. In our studies, we found that a single cycle of
methotrexate could control anti-allograft antibody responses in
heart allograft transplantation. When combined with mATG, the
survival of a heart allograft was significantly longer.
[0086] Our studies show that a single cycle of methotrexate given
within the first week of a protein therapy can provide a long-lived
reduction of greater than 95% in ADA over many months of dosing.
This reduction in antibody titers was long-lived despite the
absence of methotrexate throughout the majority of the studies.
Furthermore, we have found that a single cycle of methotrexate can
control anti-allograft responses (e.g., in a murine allogeneic
heart transplant model), showing control over antibody responses
directed towards multiple antigens simultaneously.
[0087] Methotrexate is classically known as a dihydrofolate
reductase antagonist that is thought to kill proliferating cells by
inhibiting purine metabolism and interfering with de novo DNA
synthesis (Kremer, Arthritis Rheum, 50(5):1370-82 (2004)). It could
be easily assumed that methotrexate may simply kill the reactive
cells through this well-described mechanism, but this seems
unlikely with the single cycle regimen that we have discovered.
Methotrexate has a short half-life and is not likely to be in cells
or circulation long enough to actively kill cells three to four
months following treatment (Walling, Invest New Drugs, 24(1):37-77
(2006); Slavikova et al., Neoplasma, 25(2):211-6 (1978)). Moreover,
we find no evidence of lymphocyte depletion following methotrexate
treatment. Rather, we have surprisingly found that a single cycle
regimen of methotrexate reduces undesired antibody responses by
inducing an active mechanism of immune control, not by
indiscriminately depleting lymphocytes.
[0088] Our studies show that a single cycle of methotrexate
increases B 10 regulatory B cells as well as activated marginal
zone B cells, activated follicular B cells and activated
transitional 3 B cells. Our studies also show that a single cycle
of methotrexate increase the number of IL-10-expressing,
TGF-beta-expressing, and FoxP3-expressing B10, follicular,
transitional 2 and transitional B cells, and that this expansion is
mediated by TGF-beta. These studies also show that methotrexate
increases the expression levels of IL-10, TGF-beta, and FoxP3. The
expansion of splenic B cell populations is surprising given the
current understanding of the mechanism of action of methotrexate,
and suggests that in this dosing paradigm, methotrexate is working
in a unique, previously unknown way. Low, continual doses of
methotrexate in infliximab-treated rheumatoid arthritis patients
have been shown to reduce anti-infliximab antibody responses; yet
as exposure is continuous, this regimen is more likely to involve
constant immunosuppression, rather than tolerance induction.
Methotrexate treatment alone has been shown to reduce disease
activity in rheumatoid arthritis when given weekly in low doses. A
recent publication suggests that upon continual administration of
low dose methotrexate (every other day), autoantigen-specific T
regulatory cells appear, which may help account for the efficacy of
methotrexate treatment in rheumatoid arthritis (Xinqiang et al.,
Biomed Pharmacother, 64(7):463-471 (2010)). In contrast, the dosing
paradigm described herein for methotrexate is truly unique in that
it involves a short course of methotrexate treatment that can
provide long-lasting control of undesired immunological
responses.
[0089] Altogether, we have identified a unique dosing regimen of
methotrexate that can yield long-lasting control over several
different types of ADA responses and anti-allograft antibody
responses in tissue transplantation, as well as T cell and B cell
responses. We have found that the immune tolerance developed by
methotrexate can be transferred from one animal to another, for
example, by transplanting B cells from a tolerized animal to a
non-tolerized animal. Our data suggest that methotrexate acts
through a unique mechanism of action that involves the expansion of
activated B cell subsets that may represent regulatory B cells
active in suppressing immune responses. Furthermore, methotrexate
also may act through a mechanism of T regulatory cell
expansion.
Undesired Immune Responses in Bio-Therapy
[0090] The methods of this invention can control undesired
immunological responses (e.g., ADA responses, and other undesired
T- and/or B-cell mediated immune responses) in a variety of
biological therapies (e.g., therapy using a biologic such as
proteins, nucleic acids, carbohydrates, lipids, and metabolites).
Protein therapy refers to therapy in which the therapeutic agent is
a proteinaceous substance, including peptides and proteins. Protein
therapeutics can, for example, be enzymes, cytokines, growth
factors, immunomodulators, thrombolytics, antibodies (including
polyclonal and monoclonal antibodies), antibody fragments or
modified antibodies (e.g., Fab, F(ab').sub.2, Fv, Fd, scFv, and
dAb). For example, many enzyme replacement therapies have been
developed for patients with certain genetic diseases, including
Fabrazyme.RTM. (recombinant human alpha-galactosidase) for Fabry
disease, Cerezyme.RTM. (imiglucerase) for Gaucher disease,
Aldurazyme.RTM. (laronidase) for Mucopolysaccharidosis I (MPS I),
and Myozyme.RTM. and Lumizyme.RTM. (alglucosidase alpha) for Pompe
disease. Examples of antibody therapeutics include Campath.RTM.
(alemtuzumab), Thymoglobulin.RTM., Avastin.RTM. (bevacizumab),
Lucentis.RTM. (ranibizumab), Remicade.RTM. (infliximab),
Humira.RTM. (adalimumab), Rituxan.RTM. (rituximab), Tysabri.RTM.
(natalizumab), Simulect.RTM. (basiliximab), Zenapax.RTM.
(daclizumab), OKT30 (muromonab-CD3), Erbitux.RTM. (Cetuximab),
Mylotarg.RTM. (gemtuzumab), Herceptin.RTM. (trastuzumab), and
Benlysta.RTM. (belimumab). Examples of other protein therapeutics
include Enbrel.RTM. (etanercep), and other fusion proteins.
[0091] In many cases, undesired immune responses can be generated
in a patient against the protein therapeutic, causing variable
effects on patient outcome. Such responses occur because biologic
therapeutics often contain sequences and conformations that are
foreign to a human patient. For example, ADA interferes with
therapeutic efficacy and/or increases safety risks. ADA may cause
hypersensitivy reactions, anaphylaxis, serum sickness, immune
complex disease, acute renal failure. ADA can be monitored in
patients receiving protein therapy by a clinician using well
established methods, including ELISA and immunohistochemistry.
[0092] In some instances, a "protein therapy" as used herein refers
to a viral therapy where a viral vector is used to deliver a
nucleic acid therapeutic. Exemplary viruses used in such therapies
include, but are not limited to, adenoviruses, adeno-associated
viruses, and retroviruses. Antibodies may develop against the
capsid proteins of the virus, reducing the efficacy and increasing
the safety risks of such therapies. The methods of this invention
are useful to control undesired immunological responses (e.g., ADA
responses, and other undesired T- and/or B-cell mediated immune
responses) in viral therapies as well.
[0093] The methods of this invention also may control undesired
immunological responses in non-protein biological therapies.
Exemplary non-protein bio-therapies include, but are not limited
to, nucleic acid therapies, (e.g., antisense therapies, siRNA
therapies, and miRNA therapies).
Anti-Graft Response in Transplantation
[0094] The methods of this invention can also be used to induce
immune tolerance in a patient receiving tissue transplantation such
as renal transplantation, liver transplantation, cardiac
transplantation, and stem cell transplantation. Host versus graft
and graft versus host rejections often occur in tissue
transplantation, especially allograft and xenograft
transplantation. A single cycle of methotrexate can be used alone
or together with another immune-modulating agent, (e.g., an
immunosuppressant such as Thymoglobulin.RTM.) to manage anti-graft
antibody response. In addition, the combination of
Thymoglobulin.RTM. and methotrexate in transplantation may act to
prolong graft survival. Finally, in a case where Thymoglobulin.RTM.
would be investigated in the settings of chronic autoimmune disease
such as rheumatoid arthritis and multiple sclerosis, methotrexate
may allow for safer re-treatment of Thymoglobulin.RTM., protecting
the patient from developing significant anti-rabbit antibodies
(such as IgG and/or IgM) and/or infusion-related reactions.
Managing Undesired Immunological Responses with Methotrexate
[0095] We have found that that a single, short cycle of
methotrexate can significantly reduce undesired immunological
responses such as ADA in subjects receiving biologic therapeutics
(e.g., protein therapeutics) and anti-allograft responses in
patients receiving tissue transplantation. Reducing undesired ADA
may not only improve patient safety, but also may improve the
efficacy of a protein therapeutic through improving the protein
therapeutic's pharmacodynamics and/or pharmacokinetics.
[0096] Methotrexate, a small molecule compound, has been used to
treat patients with severe active rheumatoid arthritis, severe
psoriasis, and certain types of cancer including cancers that begin
in the tissues that form around a fertilized egg in the uterus,
breast cancer, lung cancer, certain cancers of the head and neck,
certain types of lymphoma, and leukemia (cancer that begins in the
white blood cells). Methotrexate treats cancer by slowing the
growth of cancer cells. Methotrexate treats psoriasis by slowing
the growth of skin cells to stop scales from forming Methotrexate
may treat rheumatoid arthritis by decreasing the activity of the
immune system.
[0097] Methotrexate has been studied in the context of controlling
ADA responses elicited against .alpha.-galactosidase A and
.alpha.-glucosidase. However, those studies were done with multiple
cycles of methotrexate treatment (Garman et al. Clin Exp Immunol,
137(3):496-502 (2004); Joseph et al., Clin Exp Immunol,
152(1):138-46 (2008); Mendelsohn et al., N Engl J Med, 360(2):194-5
(2009)), rather than a single cycle of methotrexate.
[0098] Our studies surprisingly show that a single cycle of
methotrexate suffices to reduce ADA and anti-allograft antibodies
significantly. In fact, in studies involving antibody therapeutics
(e.g., mATG), we show that single-cycled treatment of methotrexate
is more effective in reducing ADA than multi-cycled treatment of
methotrexate. Previous studies using methotrexate gave no
indication that a single cycle of methotrexate would be sufficient
to reduce ADA, much less that it would be more effective than
multi-cycle treatment. Methotrexate is known to be cytotoxic.
Therefore, if one had hypothesized that a mechanism for reduction
of ADA by methotrexate relied upon this property, then reducing the
number of cycles of treatment actually would have been predicted to
reduce the beneficial effects of methotrexate. Furthermore, those
previously published studies do not demonstrate the benefits of
methotrexate treatment on pharmacokinetics, pharmacodynamics,
efficacy, or safety, as surprisingly have been demonstrated herein
with a single course of methotrexate. Nor do they disclose that
methotrexate can reduce ADA in antibody therapy.
[0099] As used herein, a single cycle regimen refers to a treatment
regimen, or a treatment unit, of consecutive or non-consecutive
days and are started at preferably no more than five (e.g., no more
than three) days following the dosing of the primary protein
therapeutic or transplantation. If the primary protein therapeutic
is dosed in multiple periods, a single cycle of treatment of
methotrexate preferably does not extend past the first period of
protein therapeutic dosing. By way of example, in a weekly,
monthly, or annual protein therapy, a single cycle of methotrexate
consists of three consecutive days of methotrexate intake (e.g.,
orally), starting on day 0, the day when the primary protein
therapeutic is given to the patient for the first time, or when the
patient receives a tissue transplant. Then the patient receives a
single dose of methotrexate on day 1 (24 hours later) and on day 2
(48 hours later). A single cycle of methotrexate may also consist
of, for example, 2, 3, 4, 5, 6, 7, or 8 consecutive daily doses of
methotrexate, starting on day 0. Methotrexate also can be
administered at other times as deemed appropriate, e.g., when
managing secondary autoimmunity in e.g., a lymphocyte-depleting
therapy. A single cycle of methotrexate preferably does not last
longer than 8 days. In some embodiments, a single cycle of
methotrexate begins between 48 hours prior to and 48 hours after
the onset of the primary therapeutic treatment (i.e., the treatment
with the biologic therapeutic). For example, a single cycle of
methotrexate may begin 48 hours prior to, 36 hours prior to, 24
hours prior to, 12 hours prior to, concurrently with, 12 hours
after, 24 hours after, 36 hours after, or 48 hours after, the onset
of the primary therapeutic treatment.
[0100] Our studies also surprisingly show that a low dosage of
methotrexate suffices to manage undesired immunological responses
(e.g., ADA responses, and other undesired T- and/or B-cell mediated
immune responses) in protein therapies and transplantation.
Accordingly, in embodiments of the invention, methotrexate may be
administered in more than one cycle, but at a low total dosage. For
instance, the methotrexate can be administered in two or more
(e.g., 3, 4, 5, 6, etc.) cycles, but with a total combined dosage
of no more than 5 mg/kg in a patient.
[0101] The dosage of methotrexate will be an effective amount of
methotrexate in reducing undesired immunological responses, such as
antibody or cellular responses, when given in a single cycle. An
effective amount of methotrexate in human patients may be in the
range of 0.05 mg/kg to 5 mg/kg. In some embodiments, the effective
amount is 0.1 mg/kg to 1.5 mg/kg. In some embodiments, the
effective amount is 0.12 mg/kg to 1.28 mg/kg. In certain
embodiments, the effective amount is 0.12 mg/kg. In certain
embodiments, the effective amount is 1.28 mg/kg. The recommended
dosage of methotrexate may pose minimal safety risks because the
dosing regimen involves only a brief course of methotrexate at dose
levels that are more similar to doses for rheumatoid arthritis than
low neoplastic doses. In our studies, the total amount of
methotrexate tested in each cycle in mice was 14 or 15 mg/kg. 14
mg/kg of methotrexate in mice is equivalent to approximately 68 mg
or 5.92 mg/m.sup.2 in an average adult weighing 60 kg. Rheumatoid
arthritis patients can receive up to 25 mg of methotrexate per week
without suffering from significant toxicities. The low neoplastic
dose of methotrexate is considered to be 30 mg/m.sup.2,
significantly higher than 5.92 mg/m.sup.2. Thus, the above
recommended doses, combined with the transient nature of this
methotrexate regimen, is likely to be well-tolerated in adults. The
exact dosage and regimen of methotrexate should of course be
established by a clinician, taking into account the patient's
physical condition, age, weight, gender, other medications he/she
is taking and their known side-effects, and any other relevant
factors. The effect of methotrexate on managing undesired antibody
responses in the patient can be monitored by well known methods,
including clinical examination of the patient, symptoms, blood
tests assaying ADA or anti-allograft antibody titers,
immunohistochemical assays (e.g., C4 deposition assays and other
solid-phase antibody detection methods such as the enzyme-linked
immnuosorbent assay (ELISA) and bead-based flurometric assays). The
effect also can be monitored by measuring levels of biomarkers such
as MCP-1, IL-13, IL-6, and IL-12, which we have shown to be reduced
in level by methotrexate treatment, and transitional 2 B cells,
transitional 3 B cells, follicular B cells, marginal zone B cells,
B10 B cells, and B1 B cells, which we have shown to be increased in
number by methotrexate treatment. Additionally, TGF-beta, FoxP3,
IL-5, IL-10, IL-15, and GM-CSF may be used as biomarkers to monitor
the effects of methotrexate on undesired immune responses as
needed. The levels of biomarkers also may be used to monitor the
effects of methotrexate on T cell responsiveness to a therapeutic
(e.g., a protein therapeutic). Biomarkers for T cell activation
such as IL-2, interferon-.gamma., and TNF-.alpha., may also be
monitored as readouts for methotrexate's effect on T cell
responses.
[0102] Due to its ability to control undesired immune responses,
the single cycle methotrexate regimen of this invention can expand
the use of many protein therapeutics whose repeated uses in a given
patient have been limited in the past due to safety and efficacy
concerns. For example, the concomitant use of methotrexate with
Thymoglobulin.RTM. may expand the utility of Thymoglobulin.RTM. to
other disease settings where re-dosing is desired, such as T
cell-mediated autoimmune diseases including, but not limited to,
diabetes, lupus, scleroderma, rheumatoid arthritis, psoriasis and
multiple sclerosis. In addition, methotrexate may expand upon the
efficacy and safety of alemtuzumab, for example, in autoimmune
diseases such as multiple sclerosis, wherein alemtuzumab is usually
administered in repeated annual cycles, or in chronic B-cell
lymphocytic leukemia, wherein alemtuzumab is administered in a
12-week cycle, dosing starting at 3 mg/day (until the infusion
reactions are equal to or less than grade 2), then scaling up to 10
mg/day (until the infusion reactions are equal to or less than
grade 2), and finally moving up to 30 mg/day (on alternate days, 3
times weekly). These types of dosing regimens may potentiate
inhibitory ADA responses. Methotrexate may thus be used to control
ADA and any other undesired immune responses.
Improving Lymphocyte-Depleting Therapy with Methotrexate
[0103] An exemplary application of this invention is to use
methotrexate to improve lymphocyte-depletion therapy such as
alemtuzumab therapy in treating multiple sclerosis (MS), such as
relapsing-remitting MS. "Lymphocyte depletion" is a type of
immunosuppression by reduction of circulating lymphocytes, e.g., T
cells and/or B cells, resulting in lymphopenia. Therapeutically,
lymphocyte depletion can be achieved by a protein therapeutic such
as Thymoglobulin.RTM., humanized anti-CD52 monoclonal antibody
CAMPATH-1H.RTM. (alemtuzumab), and rituximab. Lymphocyte depletion
is desired in treatment of a number of autoimmune conditions,
including multiple sclerosis (Coles et al., Ann. Neurol. 46,
296-304 (1999); Coles et al., 2008), rheumatoid arthritis,
vasculitis, and lupus.
[0104] Lymphocyte depletion therapy may cause secondary
autoimmunity. Autoimmunity is referred to herein as "secondary
autoimmunity" when it arises subsequent to the onset of a first
("primary") disease, for example, a "primary" autoimmune disease.
Secondary autoimmunity sometimes arises in MS patients having, or
having had, lymphopenia following, e.g., lymphocyte depleting
therapy. In some individuals, secondary autoimmunity arises soon
after lymphocyte depleting therapy (e.g., treatment with
alemtuzumab). In other individuals, secondary autoimmunity may not
arise until months or years after lymphocyte depleting therapy; in
some of those individuals, by the time they develop secondary
immunity, substantial lymphocyte recovery (total lymphocyte count)
may have occurred so that they may no longer be lymphopenic.
Lymphocyte depletion may occur in the context of treatment with
antibody therapeutics or small molecule therapeutics.
[0105] Secondary autoimmunity arising in lymphopenic MS patients
can be any type of autoimmune condition other than MS, including
but not limited to thyroid autoimmunity (e.g., Graves' disease),
thrombocytopenic purpura, immune thrombocytopenia (ITP),
Goodpasture's disease, autoimmune neutropenia, autoimmune hemolytic
anemia, and autoimmune lymphopenia. In some embodiments, the
secondary autoimmunity is B cell mediated, i.e., B cell responses
and auto-antibodies are directly linked with disease development
and pathology.
[0106] Techniques for diagnosing and monitoring these autoimmune
diseases are well known to those skilled in the art, including
assessment of symptoms and medical examination such as blood
analysis. The invention contemplates the use of any known methods.
For example, autoantibody levels in a patient's body fluid (e.g.,
blood) can be determined as a means of detecting signs of
autoimmunity. Specifically, anti-nuclear antibodies, anti-smooth
muscle antibodies, and anti-mitochrondrial antibodies can be
measured. In the event anti-nuclear antibodies are detected,
additional assays can be performed to measure anti-double-stranded
DNA antibodies, anti-ribonucleoprotein antibodies, and anti-La
antibodies. Anti-thyroid peroxidase (TPO) and anti-thyroid
stimulating hormone (TSH) receptor antibodies can be measured to
detect autoimmune thyroid diseases; if anti-TPO or anti-TSH
receptor antibodies are detected, one can measure whether thyroid
function is affected by measuring free T3, free T4 and TSH levels.
Anti-platelet antibodies can be measured to detect autoimmune
thrombocytopenia, and a measurement of blood platelet levels may
serve to determine if the presence of anti-platelet antibodies is
causing a reduction in platelet number. See also WO
2010/041149.
[0107] The single cycle methotrexate regimen of this invention can
be used to improve the safety and efficacy of lymphocyte-depleting
therapy by reducing ADA as well as minimizing secondary
autoimmunity. Without wishing to be bound by theory, we believe
that methotrexate may reduce secondary autoimmunity by tolerizing
multiple autoantigens simultaneously.
[0108] Unless otherwise defined, all technical and scientific terms
used herein have the same meaning as commonly understood by one of
ordinary skill in the art to which this invention belongs.
Exemplary methods and materials are described below, although
methods and materials similar or equivalent to those described
herein can also be used in the practice or testing of the present
invention. All publications and other references mentioned herein
are incorporated by reference in their entirety. In case of
conflict, the present specification, including definitions, will
control. Although a number of documents are cited herein, this
citation does not constitute an admission that any of these
documents forms part of the common general knowledge in the art.
Throughout this specification and claims, the word "comprise," or
variations such as "comprises" or "comprising" will be understood
to imply the inclusion of a stated integer or group of integers but
not the exclusion of any other integer or group of integers. The
materials, methods, and examples are illustrative only and not
intended to be limiting.
EXAMPLES
[0109] Further details of the invention will be described in the
following non-limiting examples. It should be understood that these
examples, while indicating preferred embodiments of the invention,
are given by way of illustration only, and should not be construed
as limiting the appended embodiments. From the present disclosure
and these examples, one skilled in the art can ascertain certain
characteristics of this invention, and without departing from the
spirit and scope thereof, can make various changes and
modifications of the invention to adapt it to various usages and
conditions. Materials and methods used in these working examples
are described as follows.
[0110] Mice
[0111] Normal female C57BL/6 mice between 6 and 12 weeks of age
were used for the in vivo studies of rabbit anti-murine thymocyte
globulin polyclonal antibody (mATG) and were obtained from Jackson
Laboratories (Bar Harbor, Me.) or Taconic Laboratories (Hudson,
N.Y.). Alemtuzumab-related studies employed human CD52 (huCD52)
transgenic (Tg) mice between 6-12 weeks of age that were obtained
from Charles River Laboratories/Genzyme Corp. Mice were housed and
maintained in accordance with the Guide for Care and Use of
Laboratory Animals and under American Association for Accreditation
of Laboratory Animals Care I accreditation and all animal protocols
used in these studies were approved by the Institutional Animals
Care and Use Committee.
[0112] The huCD52 Tg mouse used for nonclinical pharmacology
studies were generated by Xenogen (Cranbury, N.J., USA). To
generate the mouse, a bacmid construct containing approximately 145
kilobases of genomic DNA from human chromosome 1 was randomly
integrated into the mouse genome of CD-1 embryonic stem cells. By
virtue of the span of human genomic DNA that this bacmid contained,
the construct included a total of 5 partial or full genes of
unknown function in addition to human CD52. The 5 partial or full
gene segments contained in the bacmid were as follows: the human
CD52 gene, the 3' end of a novel gene (DKFZP434L0117), the SH3BGRL3
gene (SH3 domain binding glutamic acid-rich protein like 3), the
gene for socius (SOC), the AIM1L (absent in melanoma 1-like) gene,
and the zinc finger protein 683 gene. Three founder lines were
generated and line 107 was established at Genzyme.
[0113] Antibody Administration
[0114] Polyclonal antibodies mATG and rbIgG were prepared as
described in Ruzek et al., Transplantation, 88(2):170-9 (2009), and
administered by intraperitoneal injection in various regimens
depending upon the experiment. Monoclonal antibody alemtuzumab was
administered intravenously as either a single injection of 0.5
mg/kg or in either a three or five day cycle of 0.5 mg/kg/day.
[0115] Myozyme.RTM. Treatment
[0116] Recombinant human alglucosidase alfa (rhGAA, marketed by
Genzyme Corp. as Myozyme.RTM.) was used as a formulated drug
product. Mice were treated weekly with 20 mg/kg of rhGAA by bolus
tail vein injection unless stated differently. All mice were
treated prophylactically with 5 to 30 mg/kg diphenhydramine (Baxter
Healthcare Corporation, Deerfield, Ill.) intraperitoneally prior to
rhGAA administration. Control animals were treated intravenously
with either sterile 0.9% saline or rhGAA-formulation buffer.
[0117] Methotrexate Treatment
[0118] Methotrexate (Calbiochem catalog #454125) was administered
at 0.5, 1.0, 2.0 or 5 mg/kg by intraperitoneal injection for 1-3
cycles, where each cycle equals either three, six or seven
consecutive days of injection depending upon the experiment. In
studies that involved monthly mATG treatment, methotrexate was
administered intraperitoneally at 5 mg/kg at 0, 24, and 48 hours
following either the initial mATG treatment or the first three mATG
treatments. In transplant studies where mATG was dosed at days 0
and 4, methotrexate was given daily at 2 mg/kg from days 0 to 6,
daily at 0.5 mg/kg from days 0 to 6, or daily at 0.5 mg/kg from
days 0 to 11.
[0119] mATG Treatment
[0120] Polyclonal antibody mATG was administered as an
intraperitoneal injection of 5 mg/kg every four weeks or as two 20
mg/kg doses given four days apart when in the transplant setting
with the first dose given on the day of transplant (day 0).
[0121] Cell Preparations from Various Tissues
[0122] For splenocyte and lymph node cell preparations single-cell
suspensions were generated from harvested mouse spleens or inguinal
and mesenteric lymph nodes by homogenization between frosted glass
slides into PBS containing 2% FCS. For splenocyte preparations, red
blood cells were lysed by 1-2 minute incubation with a red blood
cell lysis solution (BD Biosciences, San Diego, Calif.). Blood was
isolated by retro-orbital bleeding and cell preparations were
performed by lysing red blood cells with red blood cell lysing
solution (BD Biosciences) for 20-30 minutes. For all tissue
preparations, live cells were enumerated using the ViCell automated
counter (Beckman Coulter, Fullerton, Calif.). Following isolation,
all cell preparations were washed with PBS/2% FCS prior to use in
the assays described below.
[0123] Flow Cytometry
[0124] For evaluation of cell populations within different tissues,
single cell suspensions of the tissues were incubated with
fluorochrome-conjugated antibodies that included anti-mouse CD4,
CD8, CD25, CD44, CD62L (all antibodies from BD Biosciences or
eBioscience, San Diego, Calif.). Intracellular Foxp3 expression
analysis was performed according to the anti-Foxp3 manufacturer's
protocol (eBiosciences, San Diego, Calif.). Following incubation
with the antibodies, cells were washed and analyzed by flow
cytometry (FACSCanto, BD Biosciences and FCS Express software, De
Novo Software, Los Angeles, Calif.).
[0125] Cell populations evaluated were defined as follows:
[0126] total CD4 T cells: CD4.sup.+CD8.sup.-,
[0127] total CD8 T cells: CD8.sup.+CD4.sup.-,
[0128] CD4 naive cells:
CD4.sup.+CD25.sup.-CD62L.sup.+CD44.sup.-,
[0129] CD4 memory cells:
CD4.sup.+CD25.sup.-CD62L.sup.-CD44.sup.+,
[0130] naive CD8 T cells: CD8.sup.+CD44.sup.-CD62L.sup.+,
[0131] CD8 memory cells: CD8.sup.+CD44.sup.+CD62L.sup.-,
[0132] regulatory T cells: CD4.sup.+CD25.sup.+Foxp3.sup.+,
[0133] total B cells: CD19.sup.+,
[0134] B2/follicular B cells: CD19.sup.+CD21.sup.hiCD23.sup.lo,
[0135] B1 B cells: CD19.sup.+CD43.sup.+CD11b.sup.+,
[0136] transitional 1 B cells:
CD19.sup.+CD93.sup.+CD23.sup.-IgM.sup.hi,
[0137] transitional 2 B cells:
CD19.sup.+CD93.sup.+CD23.sup.+IgM.sup.hi,
[0138] transitional 3 B cells:
CD19.sup.+CD93.sup.+CD23.sup.+.mu.m.sup.lo,
[0139] marginal zone B cells: CD19.sup.+CD21.sup.hiCD23.sup.lo,
and
[0140] B10 B cells: CD19.sup.+CD5.sup.+CD1d.sup.+.
[0141] In vitro blocking studies determined that up to 100 .mu.g/ml
mATG did not prevent detection of these populations.
[0142] Anti-mATG IgG ELISA
[0143] The levels of anti-mATG IgG in mouse serum were analyzed by
enzyme linked immunosorbent assay (ELISA). Briefly, 96-well plates
(Corning Inc., Corning, N.Y., USA) were coated overnight with 1
.mu.g/ml of rabbit IgG in phosphate buffered saline (PBS).
Following blocking with Super Block Blocking Buffer (Thermo
Scientific, Rockford, Ill., USA) serial dilutions of serum were
added in duplicate to rabbit IgG-coated plates and incubated at
37.degree. C. for 1 h. The plates were washed and horseradish
peroxidase-conjugated goat anti-mouse IgG secondary antibody
(Southern Biotechnology Associates, Birmingham, Ala., USA) was
added and allowed to incubate for 1 h at 37.degree. C. Following a
final wash, 3,3',5,5'-tetramethylbenzidine substrate (BioFx, Owings
Mills, Md., USA) was added and allowed to develop for 15 min at
room temperature. The reaction was stopped by the addition of 1 N
HCl and absorbance values were read at 450/650 nm on an ELISA plate
reader (Molecular Devices, Sunnyvale, Calif., USA). End-point
titers were defined as the lowest dilution that averages above an
absorbance of 0.100 using Softmax software (Molecular Devices,
Sunnyvale, Calif., USA).
[0144] mATG-Specific IgG ELISA
[0145] Mouse serum was determined by ELISA. Briefly, 96-well plates
(Corning Inc., Corning, N.Y., USA) were coated overnight with 1
.mu.g/ml of goat anti-rabbit IgG-Fc fragment antibody (Bethyl
Laboratories, TX, USA). Following blocking with 0.5% BSA (high
purity), standard controls and serum samples were diluted as
necessary and added in duplicate to the wells of the coated plates
and incubated at 36-38.degree. C. for 1 hour with gentle shaking.
The plates were washed and horseradish peroxidase-conjugated goat
anti-rabbit IgG-Fc fragment antibody (Bethyl Laboratories, TX, USA)
was added as appropriate and incubated for 1 hour at 36-38.degree.
C. with gentle shaking. Following a final wash,
3,3',5,5'-tetramethylbenzidine substrate (BioFx, Owings Mills, Md.,
USA) was added and allowed to develop for 15 min at 23-25.degree.
C. The reaction was stopped by adding 1 N HCL and absorbance values
were read at 450/650 nm on an ELISA plate reader (Molecular
Devices, Sunnyvale, Calif., USA). Final concentrations were
interpolated off the standard curve. It was predetermined that the
measurement of mATG-specific IgG by this method were only modestly
affected by titers of anti-mATG IgG that were greater than
218,000.
[0146] Anti-Alemtuzumab IgG ELISA
[0147] Mice were bled 4-6 days following alemtuzumab treatment and
specific anti-alemtuzumab IgG was measured by ELISA. Briefly,
96-well plates (Corning Inc., Corning, N.Y., USA) were coated
overnight with 3 .mu.g/ml of alemtuzumab in PBS (pH 7.2). Following
blocking with 0.1% BSA in PBS, serial dilutions of serum were added
in duplicate to alemtuzumab-coated plates and incubated at
37.degree. C. for 1 h. The plates were washed, and horseradish
peroxidase-conjugated goat anti-mouse IgG secondary antibody
(Southern Biotechnology Associates, Birmingham, Ala., USA) was
added and allowed to incubate for 1 h at 37.degree. C. Following a
final wash, TMB substrate (BioFx, Owings Mills, Md., USA) was added
and allowed to develop for 15 min at room temperature. The reaction
was stopped by the addition of 1 N HCl and absorbance values were
read at 450/650 nm on an ELISA plate reader (Molecular Devices,
Sunnyvale, Calif., USA). End-point titers were defined as the
antilog of the logarithmically transformed sample dilution
interpolated at an absorbance value of 0.2 using Excel software
(Microsoft, Redmond, Wash., USA).
[0148] Anti-rhGAA IgG ELISA
[0149] Mice were bled 4-6 days following rhGAA treatment and
specific IgG was measured by ELISA. Briefly, 96 well plates
(Corning Inc., Corning, N.Y., USA) were coated overnight with 5
.mu.g/ml of rhGAA in sodium acetate buffer (pH 5.0). Following
blocking with 0.1% BSA in PBS, serial dilutions of serum were added
in duplicate to rhGAA-coated plates and incubated at 37.degree. C.
for 1 hour. The plates were washed, and HRP-conjugated goat
anti-mouse IgG secondary antibody (Southern Biotechnology
Associates, Birmingham, Ala.) was added and allowed to incubate for
1 hour at 37.degree. C. Following a final wash,
3,3',5,5'-tetramethylbenzidine substrate (TMB, KPL, Gaithersburg,
Md.) was added and allowed to develop for 15 minutes at room
temperature. The reaction was stopped by the addition of 1N HCl and
absorbance values were read at 450/650 nm on an ELISA plate reader
(Molecular Devices, Sunnyvale, Calif.). Endpoint titers were
defined as the reciprocal of the sample dilution resulting in an
absorbance value of 0.2 using Softmax software (Molecular Devices,
Sunnyvale, Calif.).
[0150] Ex Vivo Studies
[0151] C57BL/6 (Jackson Laboratories) or E4GAAKO (Charles River)
mice 8-12 weeks old were given 5 mg/kg of methotrexate (Calbiochem
catalog #454125) by intraperitoneal injection for 1-3 cycles, where
1 cycle equals 3 consecutive injection days. 20 mg/kg of
Myozyme.RTM. (Genzyme Corporation) was given by tail vein injection
once or for 2-6 weekly doses, commencing with the first
methotrexate dose Animals were sacrificed weekly or daily after
initiation of treatment. Spleen, mesenteric, and inguinal lymph
nodes were collected for flow cytometric analysis of T and B cell
subsets and sera was collected for ELISA assays. Spleens were
processed between glass slides and red blood cells (RBC) was lysed
with lysing buffer purchased from BD Biosciences (catalog#555899)
according to the manufacturer's instructions. Lymph nodes were
processed between glass slides and washed with phosphate buffered
saline (PBS) containing 2% fetal calf serum (FCS). Cells were
resuspended in 200 .mu.L of PBS containing 4% fetal bovine serum
and 25 .mu.g/mL of total mouse IgG and blocked for 30 minutes at
4.degree. C. Approximately 3 million spleens cells and 1 million
lymph node cells were stained with different antibody cocktails and
analyzed with a high through put sampler (HTS) on a Becton
Dickinson CANTOII flow cytometer. At least 100,000 cell events were
acquired within the lymphocyte gate. Anti-mouse antibody cocktails
consisted of PE-CD21/35 catalog #552957, FITC-catalog #553138,
PE-CD138 catalog #553714, PE-CD127 catalog #552543, APC-Cy7-CD19
catalog #557655, FITC-CD43 catalog #553270, PE-Cy7-CD4 catalog
#552775, FITC-CD3e catalog #553062, APC-CD11b catalog #553312,
PE-Cy7-IgM catalog #552867, APC-Cy7-CD8 catalog #557654, PE-CD273
(PD-L2) catalog #557796, APC-CD138 catalog #558626, PE-Cy7-CD11b
catalog #552850, PE-CD93 (early B lineage) catalog #558039,
APC-CD69 catalog #560689, Pe-Cy7-CD24 catalog #560536, FITC-CD1d
catalog #553845, APC-CD5 catalog #550035, and Percp-Cy5-7AAD
catalog #559925, all purchased from BD Pharmingen. FITC-FoxP3
intracellular staining kit was purchased from eBioscience. Pacific
Blue (PB)-CD25 catalog #102022, PB-CD23 catalog #101616 and PB-CD86
catalog #105022 were purchased from BioLegend. Analysis of
lymphocyte subsets was performed with FCS express version 3
software provided by De Novo Software. Percentages were generated
with the batch processing option and absolute numbers were
calculated according to the cell counts obtained. Spleen and lymph
node cell counts were obtained with a Beckman Coulter Vi-cell XR
cell viability analyzer according to the manufacturer's
instructions.
[0152] In Vitro and Cytokine Analysis
[0153] C57BL/6 (Jackson Laboratories) or E4GAAKO (Charles River)
mice 8-12 weeks old were given 5 mg/kg of methotrexate (Calbiochem
catalog #454125) by intraperitoneal injection for 1 cycle (3
consecutive daily doses) commencing with treatment with 20 mg/kg of
rhGAA. For the 1D11 studies, animals were treated with
intraperitoneal injections of 5 mg/kg of either 1D11 or 13C4
(Genzyme Corporation) 3 time per week, every other day, commencing
with rhGAA and methotrexate treatment. Animals were sacrificed on
day 6 or 7 post rhGAA initiation depending on the mouse strain.
Spleens were prepared in single cell suspension and loaded onto the
RoboSep (STEMCELL technologies) instrument according to the
manufacturer's instructions and subjected to B cell negative
selection. Purified B cells were seeded at 500,000 cells per well
in 96 well round bottom plates (Costar catalog #3799) and either
incubated with no stimulation or with 10 .mu.g/mL of LPS (Sigma
catalog #L5014) for 48 hours at 37.degree. C. All wells received
Monensin (BD Bioscience catalog #554724) according to the
manufacturer's instructions. Cells were allowed to incubate for at
least 4 hours at 37.degree. C. Samples were transferred to V bottom
wells (USA Scientific catalog #651201) and spun at 1200 rpm for 5
minutes at 4.degree. C. Cells were resuspended in 200 .mu.L of PBS
containing 4% fetal bovine serum and 25 .mu.g/ml of total mouse IgG
and blocked for 30 minutes at 4.degree. C. Plates were spun again
and resuspended in 90 .mu.L of PBS/2% FCS with the addition of 10
.mu.l of antibody cocktail as described above, and incubated for 20
minutes at 4.degree. C. with the addition of 5 .mu.L 7AAD for the
last 10 minutes of the staining procedure. Addition of 100 .mu.L of
buffer to the samples with subsequent spin was used as a wash.
Samples could be resuspended in buffer for surface analysis of
protein and immediate acquisition or resuspended in Fix/Perm
(eBioscience catalog #11-5773) for intracellular staining of IL-10
(BioLegend catalog #505008), TGF-beta (BioLegend catalog #141404)
and FoxP3 (eBioscience catalog #11-5773-82) according to the
manufacturer's instructions. Additional surface staining included
TGF-beta and Tim-1 (BioLegend catalog #119506) antibodies. All
samples were acquired and analyzed as described above.
[0154] Animals and Cardiac Allograft Model
[0155] C57BL/6 and BALB/c mice were obtained from Charles River
(Kingston, N.Y. or Raleigh, N.C.) and used in these experiments
between 8 and 13 weeks of age. The donor allogenic C57BL/6 mice
were first anesthetized with an intraperitoneal injection of
Ketamine (Fort Dodge Animal Health/Pfizer, Fort Dodge, Iowa) and
Xylazine (Lloyd, Shenandoah, Iowa) and a median sternotomy was
performed. The donor heart was slowly perfused in situ with 1 ml of
cold heparinized Ringer's lactate solution (Baxter Healthcare,
Deerfield, Ill.) through the inferior vena cava and aorta before
the superior vena cava and pulmonary veins were ligated and
divided. The ascending aorta and pulmonary artery were then
transected, the graft removed from the donor and the heart was
stored in ice-cold saline until engraftment. A recipient mouse
(Balb/c) was similarly anesthetized and prepped as described above
for donor mice, except that the abdominal cavity was opened. Using
a surgical microscope to view the opened abdominal cavity, the
abdominal aorta (AA) and the inferior vena cava (IVC) was isolated.
The donor heart was placed into the recipient abdomen (upside down)
and the grafts revascularized with end-to-side anastomoses between
the donor pulmonary artery and the recipient inferior vena cava, as
well as the donor's aorta and the recipient abdominal aorta. After
hemostasis was confirmed, the abdominal muscle was closed with a
running 5-O Vicryl suture (Ethicon, Johnson & Johnson,
Somerville, N.J.), and the skin closed with running 5-0 Ethilon
suture (Ethicon). Standard post-op pain assessment and management
was performed. Grafts were assessed by palpation 5-7 times per week
for the first 30 day, and then 3-4 times per week until the end of
the study.
[0156] C57Bl/6 mice were treated with one 20 mg/kg intravenous dose
of rhGAA (Genzyme Corporation), 3 consecutive intraperitoneal doses
of 5 mg/kg methotrexate (APP Pharmaceuticals, LLC), and either 1D11
or 13C4 at 5 mg/kg (Genzyme Corporation) for 3 doses every other
day. Methotrexate, 1D11, and 13C4 treatment commenced with rhGAA
injections. Spleens were collected 7 days after treatment
initiation and were processed as described above for B cells,
culture and flow analysis. Additionally, rhGAA titer data was
obtained by treating animals as described above, with rhGAA dosed
weekly over 12 weeks, methotrexate dosed for either 1 or 3 cycles,
and 1D11 or 13C4 dosed 3 times a week every other day for 12 weeks.
Serum samples were collected every 2 weeks for ELISA analysis.
[0157] Histopathology and Immunohistochemistry
[0158] Cardiac grafts were fixed in 10% neutral buffered formalin,
bisected along the longitudinal axis to expose the right and left
ventricles and the outflow tract, and routinely processed for
paraffin embedding. Sections were cut at 5 microns and were stained
with hematoxylin and eosin (H&E) or Masson's trichrome. Serial
sections were also immunostained as described below. Each
H&E-stained section was evaluated qualitatively for various
features of allograft rejection pathology (e.g., vasculitis,
myocardial degeneration and necrosis, myocarditis) using a
histologic grading scheme.
[0159] Immunohistochemistry was performed using a Bond-Max
automated immunostaining system (Leica Microsystems Inc., Buffalo
Grove, Ill.). To detect CD3 and Foxp3 dual immunopositive cells,
graft tissue sections were subjected to double immunostaining with
anti-CD3 and anti-Foxp3 antibodies using Bond Polymer Refine
Detection kit and Bond Polymer AP Red kit (Leica, Buffalo Grove,
Ill.) following manufacturer's guidelines. Briefly, deparaffinized
sections of paraffin-embedded grafts were subjected to heat-induced
epitope retrieval (25 min at 99.degree. C.), incubated with serum
free protein block (Dako, Carpentaria, Calif.), rabbit monoclonal
anti-CD3 antibody (Lab Vision/Neo Marker), peroxidase-conjugated
polymer, peroxidase block, and diamino benizidene detection reagent
followed by rat anti-mouse Foxp3 antibody (eBioscience Inc., San
Diego, Calif.) and then a rabbit anti-rat antibody (Vector
Laboratories, Inc., Burlingame, Calif.). Slides were then incubated
with Bond Polymer AP and mixed red detection reagent and finally
counterstained with hematoxylin. In negative control slides,
primary anti-CD3 and anti-Foxp3 antibodies were replaced with
Chromepure whole rabbit IgG (Jackson ImmunoResearch Laboratories,
Inc., West Grove, Pa.) and rat IgG2a (AbD Serotec, Raleigh, N.C.),
respectively.
[0160] Serum Alloantibody Levels
[0161] Serum alloantibody levels were determined by incubating
serum from cardiac transplanted or normal mice at 1:50 dilutions
with an SV40 transformed C57BL/6 fibroblast line (SVB6) followed by
detection of fibrobast bound antibodies (alloantibodies) using FITC
rabbit anti-mouse IgG (Dako, Carpinteria, Calif.) and by flow
cytometric analysis. Geometric mean fluorescent intensities of
serum stained fibroblasts were divided by isotype control stained
fibroblasts to normalize alloantibody levels between experiments.
The binding of serum antibodies to allogenic fibroblasts were
specifically alloantibodies because the same serum samples did not
bind to a SV40 transformed BALB/c fibroblast line (SVBalb) (data
not shown).
[0162] Adoptive Transfer Mouse Model
[0163] C57BL/6 mice were obtained from Jackson Laboratories and
were housed under specific pathogen free conditions. Control mice
were given a single intravenous injection of rhGAA at 20 mg/kg.
Tolerized mice were given a single intravenous injection of rhGAA
at 20 mg/kg, in addition to three daily consecutive methotrexate
intraperitoneal injections of 0.5 mg. Spleens were harvested on day
six after the initial rhGAA injection, from both donor groups, and
processed into pooled single cell suspensions. Cells were washed
and filtered through a 0.22 .mu.M filter. Cells were then enriched
for B cells using a StemCell Technologies RoboSep cell separation
system, and resuspended to allow for a 200 .mu.l intravenous
injection. Tolerized and non-tolerized recipient groups received
either a high cell 10.times.10.sup.6 or a low cell 5.times.10.sup.6
concentration via intravenous injections. Control groups were given
rhGAA only, or rhGAA and methotrexate (single cycle of three
consecutive daily MTX injections). All groups received weekly
intravenous rhGAA 20 mg/kg injections, and were retro-orbitally
bled biweekly for 16 weeks, into BD Vacutainer serum separator
tubes. Serum was removed and stored below -20.degree. C. until used
for ELISA. Anti-rhGAA antibody titers were determined using ELISA,
read on a SpectraMax M2, and calculated using Softmax to
extrapolate titer value. Raw data Softmax files and EXCEL
spreadsheets containing control and titer information were stored
on network servers. All graphs and statistics were generated using
GraphPad Prism software.
Example 1
Anti-Drug Antibodies are Produced in Response to Antibody
Therapeutics
[0164] Polycloncal antibody mATG binds to a variety of immune cell
types, including antigen-presenting cells. Our data show that a
single course of mATG (two doses of 25 mg/kg given three days
apart, administered intraperitoneally) could generate anti-mATG IgG
titers as high as 100,000 (FIG. 1A) in mice. When given as
successive monthly injections (5 mg/kg, every 4 weeks), anti-mATG
titers were further increased with titers up to 5.times.10.sup.6
after five monthly injections (FIG. 1B). For both the single course
and the monthly injections, rabbit IgG (rbIgG) was used as a
control.
[0165] As alemtuzumab does not cross-react with murine CD52,
preclnical studies with alemtuzumab must be done in huCD52 Tg mice
where the transgene expression pattern is similar to CD52
expression in humans. Similar to mATG, intravenous administration
of alemtuzumab (0.5 mg/kg) elicited significant ADA responses in
huCD52 Tg mice. These responses increased through the first four
treatments and then declined such that following the fifth dose of
alemtuzumab, huCD52 Tg mice no longer generated anti-alemtuzumab
antibodies (FIG. 2). This non-responsiveness suggests that natural
tolerance had occurred (Rosenberg et al., Blood, 93(6):2081-8
(1999)).
[0166] The data show that the ADA titers against mATG in the
C57BL/6 mice and the ADA titers against alemtuzumab in the huCD52
Tg CD1 mice were high (>100,000). This high level of
immunogenicity may be attributed to the ability of mATG and
alemtuzumab to bind antigen-presenting cells, thereby enhancing
antigen processing and presentation for inducing immune responses
against them.
Example 2
Methotrexate Controls Anti-mATG IgG Responses with a Single Cycle
of Administration
[0167] Elevated antibody titers have been reported following
Thymoglobulin.RTM. treatment, and case reports of serum sickness,
acute renal failure and cardiovascular reactions have been
described in patients treated with Thymoglobulin.RTM. (Boothpur et
al., supra; Lundquist et al., Liver Transpl, 13(5):647-50 (2007);
Busani et al., Minerva Anestesiol, 72(4):243-8 (2006); Tanriover et
al., Transplantation, 80(2):279-81 (2005); Buehler et al., Clin
Transplant, 17(6):539-45 (2003)). To determine if methotrexate
could reduce anti-ATG responses, and thus, mitigate these safety
concerns, a three-day regimen of methotrexate, given only as a
single cycle, was evaluated as a means of controlling anti-mATG IgG
responses in mice. This is distinct from the regimen that was
previously published in that only a single cycle of methotrexate
was administered with mATG as opposed to at least three cycles that
were given in the context of ERTs. Methotrexate (Calbiochem catalog
#454125) administered intraperitoneally at 5 mg/kg for six
consecutive days starting on the first of two mATG administrations
(25 mg/kg, 3 days apart) could suppress anti-mATG IgG responses
through at least eight weeks following treatment by 95% when
comparing area under the effect curves (FIG. 3).
[0168] Next, the effect of methotrexate on anti-mATG titers
following five monthly injections of mATG at 5 mg/kg/injection was
evaluated. Monthly injections of mATG treatment were performed
because lymphocyte repopulation is near complete one month
following mATG treatment (Ruzek, supra). Anti-drug antibody
responses were then quantified weekly through 20 weeks of monthly
treatments. During this period, despite CD4+ T cell depletion by
mATG, antibody titers reached as high as 5 million (FIG. 1B).
Interestingly, animals that received non-specific rabbit IgG at the
same dose level and schedule as mATG showed low anti-rabbit IgG
responses (FIG. 1B). One possibility for the enhanced
immunogenicity of mATG may be the specific binding of mATG to
antigen presenting cells (APCs) such as follicular dendritic cells,
which when in the presence of complement may significantly enhance
B cell responses. Two treatment regimens of methotrexate also were
evaluated. In previous work with enzyme-replacement therapy (ERT),
three cycles of methotrexate given during the first three doses of
acid alpha-glucosidase provided a sustained reduction in antibody
titer through at least eight months of weekly ERT dosing (Joseph et
al., Clin Exp Immunol, 152(1):138-46 (2008)). A similar course of
methotrexate was evaluated in the context of mATG where 5 mg/kg of
methotrexate was given within 15 minutes of mATG administration as
well as 24 and 48 hours following each of the first three monthly
mATG treatments. This regimen successfully decreased anti-mATG
antibody responses from titers of approximately 4 million to titers
of 816,000, yielding a reduction of 79% comparing area under the
effect curves (FIG. 4A).
[0169] Additionally, the effect of a single course of methotrexate
given around only the first of five monthly mATG treatments on
anti-mATG IgG responses was evaluated and compared directly with a
three-cycle regimen. Surprisingly, this single cycle regimen
reduced anti-mATG IgG titers even further than the three-cycle
regimen, to a titer of approximately 50,000 (FIG. 4B). Comparing
area under the effect curves, the single cycle regimen reduced
anti-mATG IgG titers by 98%, while the three cycle regimen reduced
titers by 69% (FIG. 4C). The increased effects of the single-cycle
versus three-cycle regimen suggests that increasing methotrexate
exposure may actually antagonize its tolerizing effects, perhaps by
killing the cells that are mediating the control over antibody
titer.
Example 3
Methotrexate Induces an Active Mechanism of Immune Tolerance
[0170] As shown above, a very brief course of methotrexate can
significantly control antibody responses through multiple rounds of
antigen challenge. In this context, the brief cycle was a single
cycle of methotrexate that produced lasting effects (on both
antibody titers and cytokine levels) over the course of months of
testing. This long-lived control of the antibody response suggests
that methotrexate can successfully induce immune tolerance.
Methotrexate had thus far been evaluated in the context of five
consecutive monthly doses of mATG. To further evaluate whether an
immune tolerance mechanism had been activated, animals that
originally received five monthly mATG injections were withheld from
treatment for eight weeks. Following this rest period, the animals
were given a final injection of mATG. If a mechanism of immune
tolerance was employed, anti-mATG IgG titers should not increase
significantly following the sixth mATG treatment.
[0171] Our data show that animals that were not dosed with
methotrexate experienced an increase in anti-mATG IgG titers, as
expected (FIG. 5). By contrast, animals that received just one
cycle of methotrexate with the first injection of mATG did not
generate significantly greater anti-mATG IgG titers (FIG. 5). A
similar trend was observed in animals treated with three cycles of
methotrexate, though the effect was not as dramatic (FIG. 5). When
comparing area under the effect curves, the single course of
methotrexate reduced titers by 99% while the three cycle regimen
reduced titers by 85%. These data indicate that methotrexate can
maintain control over recall responses, suggesting that the mice
have developed tolerance against this antigen.
[0172] Although methotrexate-treated animals generated measurable
titers that increase with successive mATG treatments, overall,
titer levels in methotrexate-treated animals were consistently
100-fold lower than those observed in animals treated with mATG
alone (FIG. 6). The lower level of antibody titers should
significantly reduce the potential for safety risks and efficacy
effects. Although not wishing to be bound by theory, these data
suggest that an active mechanism of control has been induced that
can significantly reduce anti-mATG IgG responses, and is maintained
long after methotrexate treatment.
Example 4
A Single Cycle of Methotrexate can Significantly Control
Anti-Alemtuzumab Responses
[0173] In relapsing-remitting multiple sclerosis, alemtuzumab is
dosed in annual cycles and patients can generate ADA (Coles et al.,
N Engl J Med, 359(17):1786-801 (2008)). As immunogenicity and
pharmacokinetic testing is ongoing in multiple phase III studies,
it is unclear whether anti-alemtuzumab antibodies will impact
exposure, efficacy, and/or safety in a subset of patients. Thus, we
evaluated whether a single cycle of methotrexate could control ADA
titers following five monthly single injection cycles of
alemtuzumab. HuCD52 Tg mice were given alemtuzumab (0.5 mg/kg)
intravenously monthly for five consecutive months. Methotrexate was
given at 0.5, 1 or 5 mg/kg 15 minutes prior to the first monthly
alemtzumab dose as well as 24 and 48 hours after the dose. 1 mg/kg
of methotrexate provided some benefit, as it reduced
anti-alemtuzumab responses by 88% (FIG. 7A). 5 mg/kg of
methotrexate successfully reduced anti-alemtuzumab IgG responses by
99% (FIG. 7A). Methotrexate appeared to have no effect on natural
tolerance.
[0174] A second study confirmed the above findings. As above,
huCD52 transgenic mice were treated with five monthly doses of 0.5
mg/kg alemtuzumab. The mice also were treated with or without three
daily doses of 5 mg/kg/day of methotrexate in connection with the
first administration of alemtuzumab (FIG. 7B). Serum samples were
collected throughout the study to assess anti-alemtuzumab titers
and confirm tolerance. Titer data were obtained at 24 hours after
the fifth monthly dose. The data demonstrated that methotrexate
reduced anti-alemtuzumab antibody titers (FIG. 7C).
Example 5
Methotrexate can Control Anti-Alemtuzumab Antibody Responses in the
Context of a Clinically Relevant Alemtuzmab Dosing Regimen
[0175] A series of experiments was conducted to evaluate if
methotrexate could successfully control ADA in the context of a
clinically-relevant dosing scheme of alemtuzumab in huCD52 Tg mice.
In the clinic, alemtuzumab is dosed as an initial cycle of five
daily treatments of 12 mg/day. Twelve months following the initial
treatment cycle in patients, an additional cycle of three daily 12
mg doses of alemtuzumab is administered. At the time of the second
treatment cycle, the levels of circulating CD 19.sup.+ B cells have
recovered to baseline values; however, the levels of circulating
CD4.sup.+ T helper cells and CD8.sup.+ T cytotoxic cells have not
fully repopulated (Coles et al., N Engl J Med, 359(17):1786-801
(2008)).
[0176] Initially, the depletion and repopulation kinetics of
circulating T and B cell subsets following five daily treatments of
alemtuzumab was investigated in huCD52 Tg mice. In the peripheral
blood of huCD52 Tg mice treated with alemtuzumab for five
consecutive days with 0.5 mg/kg (equivalent to the 12 mg/kg human
dosage) via intravenous injection, total CD3.sup.+ T cells,
CD4.sup.+ T helper cells, and CD8.sup.+ T cytotoxic cells did not
recover to pre-treatment levels four weeks following treatment,
while the numbers of CD19.sup.+ B cells returned to control levels
(FIGS. 8A-D).
[0177] In order to simulate the cellular environment experienced by
patients at the time of retreatment, alemtuzumab was
re-administered in huCD52 Tg mice between 4 and 5 weeks following
the first cycle. Since the initial course of alemtuzumab was a
five-day cycle, methotrexate was administered 15 minutes prior to
each daily alemtuzumab treatment and for two days afterwards. The
maximal cumulative cycle dose of methotrexate given in this regimen
is 14 mg/kg (2 mg/kg/day), which is very similar to the cumulative
dose of 15 mg/kg when methotrexate is given as a three-day course
of 5 mg/kg/day. We evaluated the effects of 2, 1 and 0.5 mg/kg/day
administration of methotrexate on anti-alemtuzumab antibodies over
three alemtuzumab treatment cycles. At 1 mg/kg, methotrexate
appeared to control titers in 7 of the 8 mice tested and overall
reduced titers by 79% (FIG. 9B). At 2 mg/kg, methotrexate
successfully reduced ADA by 98% when comparing area under the
effect curves (FIG. 9A).
Example 6
Methotrexate can Improve the Pharmacokinetics and Pharmacodynamics
of mATG
[0178] ADA can interfere with the pharmacokinetics and
pharmacodynamics of protein therapeutics. We evaluated whether
anti-mATG IgG ADA responses interfered with mATG pharmacokinetics.
Mice were treated for five months with monthly injections of either
mATG alone or mATG with a single cycle of methotrexate.
Methotrexate was administered at 5 mg/kg daily for three doses.
Blood was sampled at various times after month 1, month 3, and
month 5 to assay the level of circulating mATG (FIG. 10).
[0179] At month 1, the levels of circulating mATG were similar
among both treatments groups, but at months 3 and 5 only the
methotrexate-treated group had measurable levels of circulating
mATG. Without methotrexate administration, the levels of mATG
measured following the third and fifth mATG doses were
significantly lower than those measured after the first dose (FIG.
10). Previous studies have shown that methotrexate significantly
reduces anti-mATG IgG responses. Thus, it appears that antibodies
against mATG interfere with mATG exposure and pharmacokinetics.
[0180] As antibodies against mATG appear to significantly reduce
the levels of circulating mATG following repeat dosing, it may be
expected that the pharmacodynamics of mATG when redosed is
negatively affected as well. Lymphocyte depletion in the blood,
spleen and lymph nodes was evaluated after the fifth monthly mATG
treatment, when titers were at their highest. As described above,
animals treated with methotrexate were only given a single cycle of
treatment.
[0181] Levels of circulating CD4.sup.+ and CD8.sup.+ T cells were
unchanged after the fifth mATG treatment in animals treated with
mATG but not methotrexate. However, in animals treated with mATG
and one cycle of methotrexate, circulating CD4.sup.+ and CD8.sup.+
T cells were significantly depleted (FIG. 11). This effect was
similarly observed in spleen and lymph nodes as well. Methotrexate
treatment enhanced the ability of mATG to increase the percentage
of T regulatory cells in the spleen and blood (FIGS. 12A-B). A
similar effect was observed in blood and lymph nodes. The enhanced
presence of T regulatory cells following mATG and
Thymoglobulin.RTM. treatment has been postulated to contribute to
the efficacy of this therapeutic (Ruzek et al., Blood,
111(3):1726-34 (2008)). The ability of methotrexate to help
maintain this effect following successive courses of mATG is a
potential added benefit of significantly reducing antibody
anti-rabbit IgG titers.
[0182] Thus far, pharmacokinetic and efficacy studies suggest that
anti-mATG antibodies interfere with the exposure and efficacy of
mATG. A direct comparison between anti-mATG IgG titer and mATG
exposure reveals that when end-point titers are greater than
10,000, the level of circulating mATG is significantly reduced
(FIG. 13a). Moreover, when anti-mATG IgG titers are greater than
100,000, mATG-mediated cell depletion is inhibited (FIGS. 13b and
13c). The R.sup.2 correlation between titer and cell depletion is
>0.7.
Example 7
Methotrexate can Improve the Pharmacodynamics of Alemtuzumab
[0183] Methotrexate not only enhances the pharmacodynamics of mATG,
but also restores alemtuzumab-mediated depletion of circulating T
and B cells when anti-alemtuzumab responses appear to neutralize
some of the depleting activity. In the studies described in this
example, five monthly intravenous injections of alemtuzumab were
given to huCD52 Tg mice with and without methotrexate. 5 mg/kg of
methotrexate was administered daily for the first three days of the
6 month study. Blood was harvested from animals of both treatment
groups two days prior to the fifth dose and one day after the fifth
dose of alemtuzumab. Cell populations were assessed by flow
cytometry as described in Example 6.
[0184] Our data show that the fifth monthly dose of alemtuzumab
appeared to no longer deplete T cells, as the absolute number of
circulating T cells seemed similar before and after treatment (FIG.
14 (each time point represents a different set of animals)). By
contrast, methotrexate appeared to have restored the ability of
alemtuzumab to deplete T cells (P=0.012). When comparing the
absolute numbers of circulating T cells in animals treated with
alemtuzumab alone and animals treated with both alemtuzumab and
methotrexate at either two days prior to or one day following
alemtuzumab dosing, the numbers of circulating T cells were
significantly lower in methotrexate-treated animals (P=0.034 and
0.02; FIG. 14). Similarly, methotrexate treatment appeared to
enhance the depletion of B cells by alemtuzumab
(P=1.2.times.10.sup.-5, P=0.02 respectively), and the number of
circulating B cells was decreased further in methotrexate-treated
animals one day following treatment (FIG. 14).
Example 8
A Single Cycle of Methotrexate can Significantly Control Anti-rhGAA
Antibody Responses
[0185] We also studied the effect of methotrexate in rhGAA enzyme
replacement therapy. In this study, the animals were injected
weekly with rhGAA for twelve consecutive weeks, then rested for
four weeks and then re-challenged with rhGAA at week 16. The
animals were also given a single cycle of three consecutive daily
doses of 5 mg/kg methotrexate at week 1, or given one cycle at each
of weeks 1, 2, and 3 (with a total of three cycles). The
rhGAA-specific IgG titers were measured in the animals at weeks 0
(prior to any treatment), 6, 8, 12, 16, 18, and 20. Our data show
that a single cycle of methotrexate controlled anti-rhGAA responses
through at least 20 weeks as well as the three cycle regimen (FIG.
15).
[0186] Studies also have been conducted in T cell deficient Nu/Nu
mice to evaluate the role of T cells in generating anti-rhGAA
titers. In these experiments, we have repeatedly observed that
little to no ADA to rhGAA develop in these T cell deficient mice
(FIGS. 37A-B). These data support the notion that T cells
contribute to anti-rhGAA titers. Thus, as methotrexate can control
ADA to rhGAA, it is also likely affecting T cell responses to
rhGAA.
Example 9
Methotrexate Enhances mATG-Mediated Survival of Heart Allogeneic
Transplants
[0187] In addition to evaluating whether methotrexate could enhance
the efficacy of mATG in normal mice, we investigated whether mATG
function could be augmented by methotrexate in a transplantation
setting. Since Thymoglobulin.RTM. is used clinically as an
induction therapy to prolong transplant survival, we evaluated
whether the addition of methotrexate could augment the efficacy of
mATG in a murine allogeneic heart transplant model. 20 mg/kg of
mATG was administered on days 0 and 4, while 2 mg/kg methotrexate
was administered as a single cycle of treatment on days 0-6.
[0188] In addition, we investigated four fold lower doses of
methotrexate (0.5 mg/kg) given under the same regimen or with an
extended regimen of 12 consecutive days. Groups of mice either
received no treatment (saline control), mATG alone, or a
combination of the mATG and methotrexate regimens. Similar to
studies in normal mice, methotrexate coadministered with mATG
reduced anti-drug antibody titers to mATG regardless of regimen
used (FIG. 16A and Table 1). Moreover, coincidental to the
reduction in antibody titers was an observed increase in mATG
exposure in this transplant setting (FIG. 16). Given the likely
adjuvant effect under the conditions of a potent, coincident immune
response against the transplanted tissue, the anti-drug antibody
titers increased even faster than in a normal mouse setting and
resulted in mATG levels being near undetectable within 7 days of
the first mATG administration (FIG. 16B). By contrast, by seven
days following transplant, anti-rabbit IgG antibody titers were
significantly lower in mice treated with methotrexate, and
circulating mATG levels were significantly higher in those mice.
This emphasizes that under conditions of an ongoing inflammatory
response, anti-drug antibody responses can be accelerated and
perhaps have an even greater impact on pharmacodynamics and
efficacy. Importantly, even under these conditions, methotrexate
had a profound inhibitory effect on mATG anti-drug antibodies and
enhanced mATG exposure. However, because circulating mATG levels
were still low to undetectable by 21 days with combination mATG and
methotrexate treatment, additional tolerance mechanisms are likely
at play given the >100 day graft survival. These results
demonstrate a remarkable synergy between mATG and methotrexate
treatment on the survival of the allogenic grafts and show a
similar level of reduction in mATG anti-drug antibodies and
enhancement of mATG exposure as observed in normal mice.
TABLE-US-00001 TABLE 1 Methotrexate regimens reduce anti-mATG
antibody titers in cardiac allograft transplant mice Average
anti-mATG Titers mATG + MTX 2 m/kg 0.5 mg/kg 0.5 mg/kg Days MTX MTX
MTX post-transplant Saline mATG Days 0-6 Days 0-6 Days 0-11 Day 14
0 1,880,820 13,500 43,740 5,400 Day 21 0 1,202,850 79,380 n/a n/a
Day 28 n/a n/a n/a 72,900 92,340 *n/a = Not available
[0189] Additional data confirmed that the combination treatment of
mATG and methotrexate significantly extended the survival of heart
allografts in addition to reducing anti-allograft responses (FIGS.
17 and 18). Indeed, while both mATG or methotrexate treatment alone
provided a modest benefit of an average extended survival to 15 and
20 days, respectively, the co-administration of mATG and any of the
methotrexate regimens evaluated demonstrated a dramatic benefit in
cardiac graft survival with the majority of mice retaining their
grafts for up to over 100 days (FIG. 17). Since cardiac graft
survival continues long after the early, brief induction treatments
of mATG and methotrexate, this regimen appears to be tolerogenic
rather than immunosuppressive. The effect was unique to the
combination of mATG and methotrexate, as other immunosuppressive
agents (e.g., mycophenolate mofetil, dexamethasone, rapamycin and
cyclophosphamide) failed to significantly prolong graft survival
when co-administered with mATG. Remarkably, methotrexate treatment
alone was able to significantly reduce anti-allograft antibodies,
further substantiating the effects of methotrexate on controlling
antibody responses in general (FIG. 18). In this scenario,
methotrexate appears to be able to control antibody responses
against multiple antigens of the heart allograft simultaneously. A
further reduction was induced by combining mATG with methotrexate
treatment (FIG. 18C).
Example 10
The Mechanism of Methotrexate-Induced Tolerance is Unique from the
Currently Known and Accepted Function of Methotrexate
[0190] The dosing regimen of methotrexate described in the Examples
above appears to invoke a mechanism that is unique from that
previously described. Methotrexate is a folate antagonist that is
thought to mediate its suppressive effects by inducing the death of
proliferating cells. mATG data presented above demonstrates that
antibody responses are induced but remain significantly decreased
with each successive mATG treatment in methotrexate-treated
animals. These data suggest that B cell responses are actively
managed. Without wishing to be bound by theory, we hypothesize that
methotrexate may induce a regulatory cell population(s) that
controls these responses as they occur. We investigated the effect
of methotrexate treatment on a variety of splenic B and T cell
subsets in animals treated with Myozyme.RTM. and methotrexate
compared with animals treated with Myozyme.RTM. alone. We observed
significant increases in the B 10 regulatory B cell population
seven and eight days following Myozyme.RTM. treatment (four and
five days after methotrexate treatment; FIG. 19).
[0191] In addition, a number of activated B cell subsets were
significantly increased following methotrexate treatment (FIG. 20).
These populations included activated marginal zone B cells,
activated follicular B cells and activated transitional 2 and 3 B
cells. Cell populations were defined as follows: B2/follicular B
cells: CD19.sup.+CD21.sup.intCD23.sup.hi; transitional 2 B cells:
CD19.sup.+CD93.sup.+CD23.sup.+IgM.sup.hi; and transitional 3 B
cells: CD19.sup.+CD93.sup.+CD23.sup.+IgM.sup.lo; marginal zone B
cells: CD19.sup.+CD21.sup.hiCD23.sup.lo. A daily assessment of
splenic cell populations in animals given two cycles of
Myozyme.RTM. and methotrexate, where Myozyme.RTM. was administered
days 1 and 8 and 5 mg/kg of methotrexate was given days 1-3 and
8-10, demonstrated that these activated B cell populations remained
increased (FIG. 21). This result is surprising because the expected
response after methotrexate treatment would be death of activated,
proliferating cells. In contrast, activated T helper, T cytotoxic
and T regulatory cell populations remained largely unchanged (FIG.
22). T helper cells were defined as CD4+, T cytotoxic were defined
as CD8+, and T regulatory cells were defined as CD4+CD25+ and
FoxP3+. These findings suggest that the increased B cell
populations may help mediate methotrexate-induced immune
tolerance.
Example 11
Methotrexate Increases Selected B Cell Populations in Combination
with mATG
[0192] In the above examples, after each mATG treatment, ADA titers
in both the mice treated with mATG alone and the mice treated with
mATG and methotrexate increased, suggesting that both sets of
animals contain B cells that are capable of contributing to an
antibody response (FIG. 6). If that is the case, at least two
hypotheses can be drawn. A first hypothesis is that methotrexate
may have killed the vast majority of B cells capable of responding
to Myozyme.RTM., and the few that remain are responsible for this
slight response. Although this is possible, flow cytometry data
from multiple experiments have not indicated a decrease in B cell
populations following Myozyme.RTM. and methotrexate treatment. A
second hypothesis is that B cell populations that can respond to
Myozyme.RTM. are not killed by this brief course of methotrexate,
but remain and are controlled by regulatory cells following each
exposure to Myozyme.RTM.. Thus far, phenotypic data describe an
enhancement of B cell subsets following methotrexate and
Myozyme.RTM. treatment. The phenotype of these B cells seems
similar to regulatory B cell subsets which have been described in
animal studies and in tolerant transplant patients. We therefore
sought to test this second hypothesis in the context of different
treatments.
[0193] Animals were treated with mATG monthly for five months and
received either a single cycle of 5 mg/kg of methotrexate on the
first three days of the study, three cycles of 5 mg/kg of
methotrexate, or no methotrexate (FIG. 23). Differences in cell
populations among the three treatment groups were then assessed by
comparing the populations in animals one day prior to the fifth
mATG dose and two days after the fifth mATG dose.
[0194] Surprisingly, five months after treatment with a single
cycle of methotrexate, differences were observed between mice that
received a single cycle of methotrexate and mATG and mice that
received either mATG alone or mATG with three cycles of
methotrexate. Two cell populations that unexpectedly demonstrated
effects were activated follicular B cells and activated
transitional 3 B cells (FIGS. 24A-B, respectively). In mice treated
with either mATG alone or in combination with three cycles of
methotrexate, decreases were observed in the absolute cell number
of these cell populations. However, in mice that received only a
single cycle of methotrexate, no statistically significant
decreases in these populations observed, suggesting that this
dosing regimen of methotrexate induced some enrichment of these
populations. Interestingly, both of these cell populations were
also shown to be enriched directly following methotrexate treatment
in combination with in Myozyme (FIG. 21). Similar subsets also have
been identified in tolerant transplant patients. It is possible
that a single cycle of methotrexate treatment can induce these B
cell subsets which, upon antigen exposure, become activated and
suppressive.
Example 12
Methotrexate Increases Selected B Cell Populations in Combination
with Alemtuzumab
[0195] As described in Example 4, huCD52 transgenic mice were
treated with single monthly doses of 0.5 mg/kg alemtuzumab for five
months, either with or without three daily doses of 5 mg/kg/day of
methotrexate in connection with the first administration of
alemtuzumab. Cell populations were evaluated in the blood and
spleen of the mice 2 days prior to, and 1, 7 and/or 28 days
following, the fifth dose of alemtuzumab by flow cytometry.
[0196] In blood, the pharmacodynamic effect of alemtuzumab was
enhanced in methotrexate-treated animals 24 hours following the
fifth dose of alemtuzumab. Statistically significant cell depletion
was observed in both T cell and B cell subsets one day after the
fifth dose, consistent with previous data indicating that
anti-alemtuzumab titers are low in these animals and would not be
likely to interfere with alemtuzumab-mediated depletion. By
contrast, mice treated with alemtuzumab alone may have more
alemtuzumab-neutralizing antibodies that interfere with alemtuzumab
pharmacodynamics. As shown in FIG. 25A, there was no significant
depletion of T cell subsets in alemtuzumab-treated mice, but mice
treated with alemtuzumab and methotrexate exhibit significant
alemtuzumab-mediated depletion in total T cells, T helper cells and
T regulatory cells one day following alemtuzumab dosing. Similar
findings were observed in circulating B cell subsets (FIG. 25B),
although trends towards decreasing cell numbers were also observed
in animals treated with alemtuzumab alone As with circulating T
cell populations, splenic T cell populations were significantly
depleted in methotrexate-treated animals one day following the
fifth alemtuzumab treatment (FIGS. 26A-B).
[0197] In contrast to T cell depletion in mice treated with
alemtuzumab and methotrexate, each of the splenic B cell
populations that were analyzed, except for follicular B cells, were
not significantly depleted (FIG. 27). This assessment includes the
regulatory B cell population, B10 B cells. Without wishing to be
bound by theory, we hypothesize that methotrexate may enrich some
or all of these B cell populations, which counters their
alemtuzumab-mediated depletion. This enrichment is not expected to
occur in the fast, fluid environment of the blood because immune
cells do not differentiate in blood. Instead, immune responses
occur in the spleen and other peripheral lymphoid tissue where
cell/cell interactions and cytokine/chemokine-initiated responses
can occur in the diverse niches of the tissue. This may explain the
differential effects of the alemtuzumab-mediated depletion of B
cells observed in blood and spleen. These data are similar to data
generated with mATG, wherein splenic B cells appeared to be
enriched in mice treated with a single cycle of methotrexate in
combination with mATG (FIG. 24A-B). Indeed, in all of the studies
described herein, enrichment following methotrexate treatment has
been observed when assessing specific populations of activated
cells. However, when assessing total numbers of a cell population
that includes both activated and non-activated cells, such as total
follicular B cells, significant enrichment in methotrexate-treated
animals was not observed.
[0198] In contrast to splenic cell populations 24 hours after
alemtuzumab treatment, three days after treatment with a single
dose of alemtuzumab (and not methotrexate), splenic cell subsets
were significantly depleted (FIG. 28A). It is possible that at 24
hours, B cell depletion may be greater in alemtuzumab-treated
animals than at three days following alemtuzumab treatment, as B
cell repopulation may have begun by the three-day mark. This has
been demonstrated in several studies assessing these populations in
peripheral blood. Depletion was observed as early as three hours
post-dosing in the peripheral blood. By three days following
treatment, circulating B cell pools were still significantly lower
in alemtuzumab-treated mice than in control mice treated with
phosphate buffered saline (PBS), although the percent depletion was
not as great as that at 24 hours. The percent depletion at 24 hours
was 92%, whereas the depletion at three days was 36% (FIG. 28B). B
cell reconstitution seems to occur rapidly following a single
dose.
[0199] In conclusion, five months after animals received
methotrexate and directly after antigen exposure, it appears that
methotrexate may have enriched B cell populations that potentially
help mediate tolerance induction. The populations that appear
enriched are similar to those that are increased directly after
methotrexate treatment (FIG. 21). Taken together, this suggests
that methotrexate may induce an environment that allows immune
responses to be actively controlled at the time of antigen
exposure, even long after the treatment with methotrexate.
Example 13
The Effects of Methotrexate on Cytokine Levels
[0200] Cytokines play a dual role in B cell responses. For
instance, B-cell activating cytokines IL-6 and BAFF are also
required for B cell differentiation. Since methotrexate seems to
increase B cell populations, one may expect these cytokines to be
increased. However, IL-6 is also pro-inflammatory, and therefore,
elevated levels may interfere with methotrexate-induced effects.
Like IL-6, IL-10 is involved in B cell differentiation into plasma
cells and immunosuppression as well.
[0201] BAFF data were generated from serum samples taken 24 hours
after the 5.sup.th dose of alemtuzumab (FIG. 29A). This is a
continuation of cellular data from this study presented above. At
this time point no difference in BAFF levels were observed (FIG.
29B).
TABLE-US-00002 TABLE 2 Study design in mice treated with
alemtuzumab and/or methotrexate Grp # Treatment Animals 1 PBS 4M/4F
2 0.5 mg/kg alemtuzumab (.times.5 days) 4M/4F 3 0.5 mg/kg
alemtuzumab + methotrexate (0.5 mg/kg for 4M/4F 8 days) 4 0.5 mg/kg
alemtuzumab + methotrexate (1 mg/kg for 4M/4F 8 days) 5 0.5 mg/kg
alemtuzumab + methotrexate (2 mg/kg for 4M/4F 8 days)
[0202] Cytokine levels were assessed one week after the second
cycle of alemtuzumab (FIG. 29B). Generally, one week after the
second cycle of alemtuzumab, cytokine levels appeared low. At this
time point, a statistically significant increase was observed in
TNF-alpha levels in animals treated with 2 mg/kg of methotrexate.
This increase may reflect a change that is related to
methotrexate-induced tolerance, or that is a sign of an
inflammatory response. Trends observed in other cytokines, such as
apparent increases in IL-6 and potentially slight decreases in
IL-7, also were noted (FIG. 30).
[0203] Regulatory B cells have been associated with IL-10
secretion. One way to assess whether IL-10-secreting regulatory B
cells play a role in methotrexate-induced tolerance is to evaluate
whether methotrexate can control antibody responses in IL-10
deficient animals. This type of assessment may be challenging in
that, as mentioned above, IL-10 is necessary for plasma cell
differentiation and therefore antibody responses may be lower in
these animals. With this caveat in mind, we observed interesting
trends suggesting that IL-10 may play a role in
methotrexate-induced tolerance.
[0204] In this study, animals received 20 mg/kg of intravenous
Myozyme.RTM. weekly for nine weeks. Three cycles of methotrexate
were administered at 5 mg/kg/day 0, 24, and 48 hours after the
first three weekly treatments of Myozyme.RTM.. Anti-Myozyme.RTM.
titers were assessed at weeks 4, 6, and 9 (FIG. 31). Comparing the
average titer values in rhGAA- and rhGAA/methotrexate-treated IL-10
knockout mice, a significant decrease in titer was not observed,
although a slight trend was observed at week 9. As expected,
antibody titers were not as high in the IL-10 knockout animals as
in the C57BL/6 wild-type animals. Anti-rhGAA responses in C57BL/6
wild-type animals treated with rhGAA and methotrexate were
decreased at 4, 6 and 9 weeks. By contrast, anti-rhGAA titers at
weeks 4 and 6 were not decreased in IL-10 knockout animals that
were treated with rhGAA and methotrexate. At week 9, there was a
slight decrease, which may indicate a delayed induction of
tolerance in IL-10 deficient mice. This would be consistent with
reports that IL-10 is not the only suppressive cytokine secreted by
regulatory B cells (Sagoo et al., J. Clin. Investigation;
120(6):1848-1861 (2010)). TGF-beta also has been associated with
the regulatory B cell response. If there is such a delay, other
cytokines such as TGF-beta may be able to help mediate the
methotrexate-tolerizing effect. These data thus far suggest that
IL-10 may play a role in methotrexate-induced tolerance.
Example 14
A Role for Methotrexate in the Treatment of Alemtumzab-Associated
Secondary Autoimmunity
[0205] Alemtuzumab-treated multiple sclerosis patients can develop
secondary autoimmunity. The most common autoimmune disorders that
develop following alemtuzumb treatment are those related to thyroid
autoimmunity. In addition, immune thrombocytopenic purpura and Good
Pasture's syndrome also have been observed in multiple sclerosis
patients treated with alemtuzumab. All three types of autoimmunity
are B cell mediated in that B cell responses and auto-antibodies
are directly linked with disease development and pathology. The
association of alemtuzumab treatment with the development of these
secondary diseases is not well understood.
[0206] Following alemtuzumab treatment, T cells and B cells are
depleted. A large percentage of these depleted T and B cells are
likely to be auto-reactive cells that interact with antigens
expressed in the central nervous system. As a result, their
subsequent depletion by alemtuzumab is thought to contribute to the
therapeutic benefit of this monoclonal antibody therapy. Patients
suffering from autoimmune disease have been described to contain
autoreactivities (i.e., autoreactive B cells and autoreactive
antibodies) against multiple antigens that are associated with a
variety of autoimmune diseases. Environmental, physiological, and
genetic factors all contribute to the determination of whether
autoimmune disease will likely ensue and influence which autoimmune
disease will present in the patient. It is not uncommon for
patients who suffer from one type of autoimmune disease to also
develop another.
[0207] In the context of alemtuzumab, one hypothesis is that
inherent autoreactivities that were not as prominent as those
related to multiple sclerosis are allowed to expand in the
lymphocyte-depleted environment following alemtuzumab treatment.
People that develop an autoimmune disease typically have
autoreactivites to a number of different antigens and therefore a
predisposition to develop other autoimmunities (i.e., "inherent
autoreactivity"). In support of this idea are data in huCD52 Tg
mice which show that alemtuzumab does not equivalently deplete all
B cell populations (FIG. 27). In fact, there appears to be an
imbalance in the B cell repertoire that favors a constituency of
low affinity autoreactive B cells, particularly marginal zone B
cells. Importantly, marginal zone B cells have been associated with
thyroid autoimmunity (Segundo et al., Thyroid, 11(6):525-530
(2001). Additionally, the regulatory B cell subset, B10 B cells,
which have been shown to help quell autoimmunity in the murine
model of multiple sclerosis, EAE (Matsushita et al., J. Clin.
Investigation, 118:3420-3430 (2008)), and have been shown to exist
in humans (Iwata et al., Blood, 117:530-541 (2011)) is depleted for
longer periods of time than marginal zone B cells. A short course
of methotrexate treatment during the first cycle of alemtuzumab may
help increase the representation of regulatory B10 B cells, and to
restore the B cell balance such that marginal zone B cells are more
equally represented in the B cell repertoire following alemtuzumab
treatment and/or differentiate the marginal zone B cells into
regulatory marginal zone B cells (CD1d+marginal zone cells).
[0208] Splenic B cell populations were studied to determine the
effects of alemtuzumab on B cell depletion (FIG. 32). 0.5 mg/kg of
alemtuzumab was administered intravenously for five consecutive
days in huCD52 Tg mice. Specifically, populations of follicular B
cells (which are typically not autoreactive), B1 B cells and
marginal zone B cells (both of which are autoreactive), B10 B cells
(which are regulatory), and transitional B cells and marginal zone
B cells (which are thought to be able to differentiate into B
regulatory cells) were examined
[0209] While follicular, B1, and regulatory B cells were depleted
at one and/or two weeks following treatment with alemtuzumab,
marginal zone B cells and transitional 1 (T1) and transitional 2
(T2) B cells were not depleted at any of the time-points (FIG. 32).
Transitional 3 B cells (T3) were only depleted after one week of
treatment, and the numbers of regulatory B cells generally appear
lower in alemtuzumab-treated mice than in control-treated animals,
although statistical significance was not observed at weeks 2 and
4.
[0210] To examine the effects of methotrexate on B cell populations
in the context of treatment with alemtuzumab, a second study was
performed as indicated in Table 3 and FIG. 33. Surprisingly,
co-treatment of methotrexate with alemtuzumab may allow for a
stronger depletion of marginal zone B cells shortly following
alemtuzumab treatment than depletion observed with alemtuzumab
alone (FIG. 34), thereby promoting a balanced immune environment
with the appropriate level of naturally occurring low-affinity
self-reactive B cells necessary for proper early response to
infection.
[0211] A group of mice treated with alemtuzumab alone was included
in this study, and revealed that mice treated only with
methotrexate in this short cycle regimen exhibited cellular effects
in the absence of antigen stimulation, which can be different from
the effects observed in control mice treated with methotrexate
alone (FIG. 34). Data generated in this study, wherein splenic B
cell populations were assessed two days following the last day of
methotrexate treatment, suggest that methotrexate may enhance the
depletion of marginal zone B cells. This supports the hypothesis
that methotrexate, when delivered with alemtuzumab, may result in a
cellular environment wherein naturally occurring B cell subsets are
appropriately in balance with non-autoreactive B cell subsets.
TABLE-US-00003 TABLE 3 Study design in mice treated with
alemtuzumab and/or methotrexate Animals Sacrifice Per time Flow Grp
# Treatment Group points data Pathology 1 0.5 mg/kg 5 Day 4 Blood,
Lymph node (LN) alemtuzumab spleen 2 0.5 mg/kg 5 Day 4 Blood, LN
alemtuzumab + spleen methotrexate (5 mg/kg) 3 0.5 mg/kg 5 Day 64 --
LN, thyroid alemtuzumab 4 0.5 mg/kg 5 Day 64 -- LN, thyroid
alemtuzumab + methotrexate (5 mg/kg) 5 0.5 mg/kg 5 Day 64 -- LN,
thyroid alemtuzumab 6 0.5 mg/kg 5 Day 64 -- LN, thyroid alemtuzumab
+ methotrexate (5 mg/kg) 7 Methotrexate 5 Day 4 Blood, LN
spleen
[0212] Based on the daily assessment of cell populations that
followed directly after methotrexate treatment with Myozyme.RTM.,
we hypothesize that in the context of alemtuzumab, B 10 B cell
populations and other potentially regulatory B cell populations
will be enriched by methotrexate no earlier than 5-6 days following
methotrexate treatment. We have not observed such populations to be
enriched as early as two days after methotrexate treatment, which
is consistent with this hypothesis. By contrast, the effects seem
to be different at longer time periods after methotrexate
treatment, as seen in the context of mATG and alemtuzumab
treatment. In both of those scenarios, five months after
methotrexate treatment, B cell subsets appeared enriched in
methotrexate-treated mice one and two days following mATG and
alemtuzumab dosing (see FIG. 35 for alemtuzumab data).
Interestingly, marginal zone B cells at this time point also
appeared increased (although this is not statistically
significant).
[0213] Methotrexate induces tolerance to protein therapies and
transplanted cardiac tissue antigens, thereby abrogating B cell
immune responses that relate to the production and secretion of ADA
and anti-allograft antibodies. We therefore hypothesize that
methotrexate may not only help control the cellular environment
following alemtuzumab treatment, but that it also may induce
tolerance to self-proteins and mitigate the B cell immune responses
that relate to the generation of auto-antibodies that contribute to
the development and pathology of B cell-mediated autoimmune
diseases.
[0214] To test this hypothesis, animals were dosed monthly for five
months with alemtuzumab. Methotrexate was given to a group of
animals at 5 mg/kg for three consecutive days following only the
first alemtuzumab treatment. Two days prior to and one day
following the fifth dose of alemtuzumab treatment, animals were
sacrificed for analysis. Serum cytokine levels were assessed before
and after alemtuzumab treatment. Surprisingly, these results
suggest that the levels of the pro-inflammatory cytokines MCP-1,
IL-13, IL-6, and IL-12 were decreased in animals treated with
methotrexate 24 hours after the fifth dose of alemtuzumab, five
months after being dosed with any methotrexate (FIG. 36). These
cytokines not only promote B cell responses and immune cell
recruitment, but they also can play a role in hypersensitivity
reactions. These data suggest that methotrexate may help deter
infusion associated reactions.
Example 15
Methotrexate Induces Immune Tolerance Through Specific Induction of
Regulatory B Cell Populations
[0215] Our data surprisingly show that methotrexate induces immune
tolerance not by the expected means of killing proliferating cells
as suggested by others (Messinger et al., Genetics in Medicine
14:135-142 (2012) and Lacana et al., Am J Med Genet Part C Semin
Med Genet 160C:30-39 (2012)), but through the specific induction of
regulatory B cells populations that express TGF-beta, IL-10 and
FoxP3. B cells from mice tolerized to Myozyme.RTM. by a single
cycle of methotrexate appeared to transfer immune tolerance to
naive animals. Moreover, both IL-10 and TGF-beta appeared to be
necessary for methotrexate-induced immune tolerance. In some cell
subsets it also appeared that methotrexate induced TGF-beta, which
in turn induced IL-10 and FoxP3. This mechanism is novel and
unexpected, and questions the value of a current clinical immune
tolerance protocol that involves co-treatment with three cycles of
methotrexate, Rituximab.RTM. (a B cell-depleting agent), and
optionally, intravenous immunoglobulin (IVIG) (Messinger et al.,
supra). Although this combination treatment appears to be
successful, our data suggest 1) that a single cycle of methotrexate
may potentially generate even lower ADA titers than those currently
observed, and 2) that if too much methotrexate and rituximab are
administered, immune tolerance may not be maintained. The initial
doses of rituximab may not be too harmful as rituximab-mediated B
cell depletion is not thought to comprehensively deplete all B
cells in the blood and tissues. As seen with the studies described
herein, although alemtuzumab actively depletes B10 B cells,
treatment with methotrexate still is able to access those cells
that seem to help maintain alemtuzumab tolerance for many months
following the initial cycle of methotrexate. Moreover, rituximab
treatment is rapidly followed by increased representation of
transitional B cells, which, as shown herein, seem influenced by
methotrexate to induce and mediate immune tolerance. As these
mechanistic data are counterintuitive and unexpected, a single
cycle of low dose methotrexate is a surprising and effective method
of inducing immune tolerance to, inter alia, lymphocyte-depleting
protein therapies.
[0216] As described above, several B cell subsets are significantly
increased in cell percentage and/or cell numbers soon after
co-administration of methotrexate with a protein therapeutic.
Moreover, these subsets appear increased in methotrexate-tolerized
mice long after a single cycle treatment of methotrexate (see,
e.g., FIGS. 24, 27, and 35). Together, these data suggest that
these cell populations may actively mediate both the induction and
maintenance of immune tolerance induction. To further substantiate
this hypothesis, we investigated whether these cell populations
expressed cytokines and other proteins often associated with immune
regulation.
[0217] One cell type associated with immune regulation is B10 B
cells. B10 B cells in both human and mouse are characterized by
their expression of IL-10 (Matsushita et al., J. Clin. Invest.
118:3420-3430 (2008), Iwata et al., Blood 117:530-541 (2011)), and
can only suppress immune responses in IL-10 competent mice. B10 B
cells were increased in methotrexate-tolerized mice (FIG. 19), and
IL-10 knockout animals were unresponsive to methotrexate-induced
immune tolerance (FIG. 31). B10 B cells isolated from animals
treated with Myozyme.RTM. or Myozyme.RTM. and methotrexate were
assessed for IL-10 protein expression by flow cytometry. Although
IL-10 was expressed in B10 cells from both treatment groups, the
number of B10 B cells expressing IL-10 was increased in animals
treated with Myozyme.RTM. and methotrexate (FIG. 38). IL-10 was
expressed in both activated, CD86+ and non-activated, CD86- B10 B
cells following two days of culture (FIG. 39). Previous studies
appear to show that IL-10 expression is measured only following in
vitro stimulation of cells by stimulants such as PMA/Ionomycin or
LPS (Carter et al., J Immunol 186:5569-5579 (2011); Yanaba et al.,
J Immunol 182:7459-7472 (2009)). Surprisingly, in our studies, the
cultured splenic B cells did not need any stimulation or
manipulation to allow for the measurement of IL-10, more directly
suggesting that these B10 B cells express IL-10 in vivo. The data
provided herein were generated in non-stimulated cultures. In
addition, we believe that we have demonstrated for the first time
that methotrexate can specifically expand cell populations that
express IL-10. Moreover, these cell populations appear to express
more IL-10 when isolated from animals treated with Myozyme.RTM. and
methotrexate than from animals treated with Myozyme.RTM. alone
(FIG. 54).
[0218] TGF-beta expression is associated with immune regulation in
T regulatory cells and is often linked with IL-10 expression in T
regulatory cells. Moreover, some reports seem to indicate that
regulatory B cells can express TGF-beta. Although B10 B cells have
never been reported to express TGF-beta, we decided to assess
TGF-beta expression in B10 B cells of mice treated with
Myozyme.RTM. alone or with Myozyme.RTM. and methotrexate using flow
cytometry. Unexpectedly, we found that B10 B cells express
TGF-beta, and that the numbers of TGF-beta-expressing cells is
increased in methotrexate-tolerized animals (FIG. 40A). Moreover,
in these cultured cells, TGF-beta is expressed in both activated
(CD86+) and non-activated (CD86-) B10 B cells (FIG. 40B). This is
an additional novel observation that methotrexate treatment
increases the numbers of cells that express TGF-beta. Additionally,
methotrexate increases the expression level of TGF-beta (FIG.
55).
[0219] FoxP3 is another protein associated with immune regulation.
FoxP3 is a marker for T regulatory cells. FoxP3 has not been
reported to be expressed in B10 B cells in mice. We investigated
FoxP3 expression in B10 B cells in the presence and absence of
methotrexate-induced immune tolerance by using flow cytometry. B10
B cells appear to express FoxP3, as seen in animals treated with
Myozyme.RTM. alone (FIG. 41A). The numbers of FoxP3+ B cells appear
to increase with treatment with both methotrexate and Myozyme.RTM.
(FIG. 41B). Additionally, both cultured activated (CD86+) and
non-activated (CD86-) B10 B cells appear to express FoxP3 (FIG.
41). This was the first report that B10 B cells express FoxP3. We
found that FoxP3 was expressed in both activated (CD86+) and
unactivated (CD86-) B10 B cells and the expression of FoxP3 is
increased with methotrexate treatment (FIG. 56).
[0220] Because additional B cell-types are significantly increased
with single cycle methotrexate-induced immune tolerance, we
assessed whether some of these cell types expressed IL-10, TGF-beta
and FoxP3. Transitional 2, transitional 3 and follicular B cells
were found to express IL-10 (FIG. 42), TGF-beta (FIG. 43) and FoxP3
(FIG. 44), which was novel and unexpected for each of those B cell
subsets. As observed with the B10 cells, the absolute cell numbers
of the IL-10, TGF-beta, and FoxP3 B cell subsets were increased
with methotrexate (FIGS. 42-44 B and C) as compared to mice treated
with Myozyme.RTM. alone (FIGS. 42-44 A and C). Methotrexate
treatment also induces statistically significant increases in
IL-10, TGF-beta and FoxP3 in multiple cell subsets as viewed by the
shift in mean fluorescence intensity of these proteins in animals
treated with Myozyme.RTM. alone or Myozyme.RTM. and methotrexate
(FIGS. 54-56).
[0221] To further investigate the multiple TGF-beta expressing B
cell populations enriched by treatment with methotrexate and
Myozyme.RTM., we next looked to determine whether TGF-beta is
required for methotrexate-induced immune tolerance. Animals were
treated with Myozyme.RTM. or Myozyme.RTM. and methotrexate with or
without the presence of 5 mg/kg of anti-TGF-beta antibody (1D11,
Genzyme) or the isotype control (13C4) given three times per week
via intraperitoneal injection throughout the study. Antibody titers
were assessed bi-weekly in four different groups of animals. If
TGF-beta was required for methotrexate-induced immune tolerance,
then we would expect that animals treated with the anti-TGF-beta
antibody should not exhibit reduced anti-Myozyme titers. Week 6
titers are depicted in FIG. 45, and suggest that TGF-beta may be
necessary for methotrexate-induced immune tolerance. Because this
is an early time point, only some of the animals have had time to
generate anti-Myozyme responses. Importantly, at this time point
titers appear similar to those shown in FIG. 15C at week 6, where
two animals in the rhGAA alone and the rhGAA- and methotrexate- and
1D11-treated animals exhibited high titers. In comparison, none of
the animals treated with rhGAA and methotrexate or rhGAA and
methotrexate and 13C4 exhibited high titers.
[0222] Additionally, spleens were isolated from animals treated
with Myozyme.RTM. or Myozyme.RTM. and methotrexate that also were
co-administered 1D11 or 13C4 seven days following a single
Myozyme.RTM. treatment or a single Myozyme.RTM. and methotrexate
treatment. At this time point, transitional 2, transitional 3, B10
and follicular B cells that expressed IL-10, TGF-beta, and FoxP3
were increased in animals treated with Myozyme.RTM. and
methotrexate. Cells in each group were then pooled and cultured for
two days and then assessed by flow cytometry to determine whether
the anti-TGF-beta treatment with 1D11 interfered with the expansion
of cells that expressed TGF-beta, IL-10, and FoxP3 in comparison to
the isotype control antibody (13C4).
[0223] Quite unexpectedly, 1D11 treatment interfered with not only
the methotrexate-induced expansion of cells expressing TGF-beta,
but also with the expansion of some subsets expressing IL-10 and
FoxP3. This was true specifically for B10 B cells (FIG. 46) and
follicular B cells (FIG. 47), though FoxP3+ Follicular B cells did
not appear to experience 1D11 effects. In transitional 2 B cells
where 1D11 treatment interfered with TGF-beta-expressing
transitional 2 B cells, no effects were seen with IL-10+
transitional 2 B cells (including activated transitional 2 B cells;
FIG. 48). Moreover, effects in FoxP3+ transitional 2 B cells by
1D11 did not seem apparent in this small treatment group unless one
looks at activated, CD86+ transitional 2 B cells. Importantly,
these data suggest that methotrexate-induced TGF-beta is associated
with IL-10 and FoxP3 in only some cell types. For transitional 3 B
cells, even though there is detectable TGF-beta in the transitional
3 subset (FIG. 49), there is no apparent effect of 1D11 treatment
on these cells (P<0.05; FIG. 49). Notably, in activated CD86+
transitional 3 B cells, there appear to be higher numbers of IL-10+
transitional 3 B cells in 1D11-treated mice. This may suggest that
this population might be expanding to try to help compensate for
losses in the numbers of other cell-types due to 1D11 treatment.
Also of note is that 1D11 treatment did not affect basal levels of
IL-10, TGF-beta, and FoxP3 in these cells (FIG. 50A-C,
respectively), but it appeared to influence methotrexate effects on
cells that express those cytokines.
[0224] In summary, interfering with TGF-beta by injecting a
TGF-beta antibody during methotrexate-induced immune tolerance
reduces the numbers of cells that are expressing TGF-beta in
comparison to animals treated with the isotype control. Moreover,
the typical increases observed with methotrexate-induced tolerance
in IL-10 and FoxP3-expressing B10 B cells are inhibited by 1D11
treatment. 1D11 treatment appears to influence methotrexate effects
on TGF-beta, IL-10, and/or FoxP3 in certain B cell types, but not
all B cell types. These observations are surprising, and suggest
that methotrexate induces TGF-beta, which in turn induces IL-10 and
potentially FoxP3 in certain cells, such as B10 B cells. Although
the association of TGF-beta with IL-10 and FoxP3 appears to have
been reported before, it has not been shown in these cell types.
Moreover, methotrexate has not been simultaneously associated with
this complex signaling cascade.
[0225] Thus far, we have demonstrated that certain B cells are
significantly increased with methotrexate-induced tolerance, and
that those B cells express proteins associated with
immune-regulation (suppression). To more directly evaluate if the B
cells themselves are mediating methotrexate-induced tolerance, we
performed an adoptive transfer experiment assessing whether total
splenic B cells from methotrexate-tolerized mice could transfer
immune tolerance to naive hosts. We performed this experiment using
Myozyme.RTM. and a single cycle of methotrexate treatment. We
isolated spleens from animals treated with Myozyme.RTM. alone or
with Myozyme.RTM. and methotrexate, 7 days after a single treatment
of Myozyme.RTM. or Myozyme.RTM. and methotrexate, (when the
above-mentioned B cell subsets were increased by methotrexate), and
then purified all of the splenic B cells. Those cells were then
transferred into Myozyme.RTM.-naive recipient mice (FIG. 51A).
After transfer, the recipients (along with non-transferred control
animals treated with either Myozyme.RTM. or Myozyme.RTM. and
methotrexate) were treated weekly with 20 mg/kg of Myozyme.RTM..
Blood was collected every other week to assess anti-Myozyme
antibody titers. At the time of harvesting spleens, a subset of B
cells from each donor group was assessed by flow cytometry to
confirm the expected increases in TGF-beta+, IL-10+ and/or FoxP3+
transitional 2, transitional 3, B10 and follicular B cells. Donor
groups were confirmed to have the expected phenotype. Titer
analysis suggested that total splenic B cells isolated from animals
treated with Myozyme.RTM. and a single cycle of methotrexate could
transfer immune tolerance to Myozyme.RTM. in naive hosts (FIG.
51B). This supports that B cells can mediate methotrexate-induced
immune tolerance, and was the first time that B cells have been
described to be enriched (and not killed) by methotrexate to help
mediate anti-inflammatory effects. These data also directly
question the concomitant use of a B cell depleting agent with
methotrexate to induce immune tolerance, which is currently being
performed in patients (Messinger et al., supra and Lacana et al.,
supra).
Example 16
Methotrexate Improves Graft Pathology
[0226] We also have generated additional data in the context of
murine anti-thymocyte globulin that demonstrates that methotrexate
does not deplete CD4+, CD8+, T regulatory (CD4+CD25+FoxP3+) T
cells, and total CD19+ B cells in normal animals (FIG. 52) and in
transplant animals (FIG. 53). When comparing normal animals treated
with non-specific rabbit IgG alone or in combination with
methotrexate, there were no significant changes in the cell
populations in the blood and spleen (FIG. 52). Moreover, when
comparing those populations isolated from animals treated with mATG
alone or with mATG and methotrexate, there was no enhanced
depletion. Rather, we observed only an extension of mATG-mediated
CD4+, CD8+, and T regulatory cell effects, which was most likely
due to increased mATG exposure by methotrexate (FIG. 52). In
addition, methotrexate treatment alone in animals receiving an
allogeneic transplant did not deplete those particular cell subsets
(FIG. 53). The lower numbers of CD4+ and CD8+ T cells in animals
treated with mATG and methotrexate compared to animals treated with
mATG alone can be explained by the prolonged effect of mATG when in
the context of methotrexate treatment. Importantly, methotrexate
did not induce decreases in B cells as would have been expected if
methotrexate was killing activated B cells to reduce antibody
responses in either normal or transplanted animals (FIGS. 52 and
53). These data suggest that methotrexate effects on anti-drug
antibodies may not be mediated by anti-folate induced depletion of
activated B cells. As expected, mATG treatment also did not impact
total B cell numbers in this heterotopic cardiac allograft model.
Overall, the combined treatment of mATG and methotrexate attenuated
the severity of graft rejection pathology and was associated with
decreased T cell infiltrate in the graft, but not with increases in
cells with a regulatory T cell phenotype. This is consistent with
the results generated in the context of Myozyme.RTM. and
alemtuzumab.
[0227] To both assess the histological changes in long-surviving
grafts as well as to understand the mechanism of mATG and
methotrexate combination on graft survival, cardiac grafts were
collected and evaluated for pathology as well as cellular
composition. In particular, because regulatory T cells have been
associated with long-term graft survival in transplantation, are
induced by Thymoglobulin.RTM. and mATG, and have been demonstrated
to be responsible for delayed graft rejection following mATG
treatment, CD3+Foxp3+ cells, which bear a phenotype consistent with
T regulatory cells, were evaluated. Specifically, cardiac grafts
were collected from the mATG and methotrexate combination-treated
group and the untreated syngeneic group at least 100 days after
transplantation. Grafts from untreated mice and mice treated with
mATG alone or methotrexate alone were taken after graft rejection
for comparison. Tissue sections stained with H&E or Masson's
trichrome or immunostained anti-CD3 and anti-Foxp3 antibodies were
microscopically evaluated for histologic changes indicative of
transplant rejection, e.g., mild to moderate myocarditis,
myocardial degeneration and necrosis, cardiac allograft
vasculopathy (CAV), and T cell infiltration. At day 100, allografts
from animals co-treated with mATG and methotrexate revealed minimal
to mild CAV lesions and no to minimal myocardial degeneration and
myocarditis. Histological changes suggestive of graft rejection
were not apparent in syngeneic grafts at this late time point (FIG.
54). Allografts from the combination treated group exhibited mild T
cell infiltration in the myocardium with a few cells infiltrating
the myocardial blood vessels. Syngeneic grafts contained rare T
cells within the myocardium. Clusters of T cells with occasional
dual CD3 and Foxp3 immunopositive cells were present in the
epicardium of both syngeneic grafts and combination-treated
allografts. Thus, long-surviving grafts showed minimal signs of
graft rejection, which correlates with reduced inflammation.
[0228] Because the effects of mATG and methotrexate combination
treatment were likely to more actively occur closer to the time of
transplantation, we also evaluated pathology and characterized the
cellular infiltrate of transplanted heart allografts at 7 (for
untreated mice) or 14 (for all treatment groups) days after
transplantation. Untreated allografts displayed graft rejection
pathology including myocarditis, myocardial degeneration and
necrosis in both epicardial and intramyocardial branches of
coronary arteries. By contrast, allografts isolated from animals
treated with both mATG and methotrexate revealed less severe CAV.
This was in comparison to allografts from untreated animals as well
as from animals treated with either mATG or methotrexate (FIG. 58).
As expected, syngeneic grafts from untreated mice revealed little
or no pathology at these time points. CD3+ T cell infiltration was
observed in the myocardium and epicardium in allografts from
untreated mice and those treated with mATG or methotrexate alone. A
few CD3+ T cells also were present in the inflammatory cell
infiltrate associated with the CAV lesions in these grafts. By
contrast, allografts from animals treated with the combination of
mATG and methotrexate exhibited substantially lower CD3+ T cell
infiltration in the myocardium and only minimal CD3+ T cell
infiltration in the epicardium. Syngeneic cardiac grafts showed
minimal CD3+ T cell infiltration only in the epicardium. A small
proportion of T cells within the inflammatory cell infiltrates in
the epicardium appeared to have a T regulatory cell phenotype as
indicated by dual CD3 and Foxp3 immunoreactivity, but this
frequency appeared no greater within inflammatory infiltrates than
in other groups. Therefore, reduced pathology also was observed
early after treatment with mATG and methotrexate and was associated
with both reduced and epicardium-restricted T cell
infiltration.
* * * * *